BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 727] [Article Influence: 75.1] [Reference Citation Analysis]
Number Citing Articles
1 Buckley JP, Cook SF, Allen JK, Kappelman MD. Prevalence of chronic narcotic use among children with inflammatory bowel disease. Clin Gastroenterol Hepatol 2015;13:310-315.e2. [PMID: 25117776 DOI: 10.1016/j.cgh.2014.07.057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
2 Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am. 2010;39:543-557. [PMID: 20951917 DOI: 10.1016/j.gtc.2010.08.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
3 Ng SC, Hilmi IN, Blake A, Bhayat F, Adsul S, Khan QR, Wu DC. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.Inflamm Bowel Dis. 2018;24:2431-2441. [PMID: 30312414 DOI: 10.1093/ibd/izy153] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 21.5] [Reference Citation Analysis]
4 Canavese G, Villanacci V, Sapino A, Rocca R, Daperno M, Suriani R, Maletta F, Cassoni P; Members of the Piedmont IBD Group. The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. Dig Liver Dis 2015;47:20-3. [PMID: 25445404 DOI: 10.1016/j.dld.2014.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
5 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
6 Hata K, Anzai H, Ikeuchi H, Futami K, Fukushima K, Sugita A, Uchino M, Higashi D, Itabashi M, Watanabe K, Koganei K, Araki T, Kimura H, Mizushima T, Ueda T, Ishihara S, Suzuki Y; on behalf of the Research Group for Intractable Inflammatory Bowel Disease of the Ministry of Health, Labour and Welfare of Japan (RGIBD). Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol 2019;114:483-9. [DOI: 10.14309/ajg.0000000000000117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
7 Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med 2011;124:e1-18. [PMID: 21531240 DOI: 10.1016/j.amjmed.2011.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Navaneethan U, Zhu X, Lourdusamy D, Lourdusamy V, Shen B, Kiran R. Colorectal cancer resection rates in patients with inflammatory bowel disease: a population-based study. Gastroenterol Rep (Oxf) 2018;6:263-9. [PMID: 30430014 DOI: 10.1093/gastro/goy030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of Illness in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62:2318-2326. [PMID: 28766243 DOI: 10.1007/s10620-017-4690-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
10 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
11 Stobaugh DJ, Deepak P, Thorpe M, Hannon B, Ehrenpreis ED. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis. 2013;19:301-308. [PMID: 22644716 DOI: 10.1002/ibd.23003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Navaneethan U, Kochhar G, Phull H, Venkatesh PG, Remzi FH, Kiran RP, Shen B. Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. J Crohns Colitis 2012;6:470-5. [PMID: 22398061 DOI: 10.1016/j.crohns.2011.10.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
13 Bar N, Avraham Y, Dubinsky V, Cohen NA, Weiss GA, Banon L, Tulchinsky H, Maharshak N, Gophna U, Dotan I. Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. Inflamm Bowel Dis 2021:izab209. [PMID: 34536075 DOI: 10.1093/ibd/izab209] [Reference Citation Analysis]
14 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
15 Lam WC, Zhao C, Ma WJ, Yao L. The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. Gastroenterol Res Pract 2019;2019:1287493. [PMID: 31178906 DOI: 10.1155/2019/1287493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
17 Zheng K, Shen H, Jia J, Lu Y, Zhu L, Zhang L, Shen Z. Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. Trials. 2017;18:8. [PMID: 28069051 DOI: 10.1186/s13063-016-1763-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
18 Cuffari C, Pierce D, Korczowski B, Fyderek K, Van Heusen H, Hossack S, Wan H, Edwards AY, Martin P. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. Drug Des Devel Ther 2016;10:593-607. [PMID: 26893546 DOI: 10.2147/DDDT.S95316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
19 Binabaj MM, Asgharzadeh F, Avan A, Rahmani F, Soleimani A, Parizadeh MR, Ferns GA, Ryzhikov M, Khazaei M, Hassanian SM. EW‐7197 prevents ulcerative colitis‐associated fibrosis and inflammation. J Cell Physiol 2019;234:11654-61. [DOI: 10.1002/jcp.27823] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
20 Kishikawa J, Hata K, Kazama S, Anzai H, Shinagawa T, Murono K, Kaneko M, Sasaki K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Ishihara S, Morikawa T, Fukayama M, Watanabe T. Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc 2018;30:236-44. [PMID: 28836702 DOI: 10.1111/den.12955] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Liu K, Jia B, Zhou L, Xing L, Wu L, Li Y, Lu J, Zhang L, Guan S. Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics and Lipidomics Identify Biomarkers for Efficacy Evaluation of Mesalazine in a Dextran Sulfate Sodium-Induced Ulcerative Colitis Mouse Model. J Proteome Res 2021;20:1371-81. [PMID: 33356298 DOI: 10.1021/acs.jproteome.0c00757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ali AH, Carey EJ, Lindor KD. The management of autoimmunity in patients with cholestatic liver diseases. Expert Review of Gastroenterology & Hepatology 2015;10:73-91. [DOI: 10.1586/17474124.2016.1095088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
23 Null KD, Xu Y, Pasquale MK, Su C, Marren A, Harnett J, Mardekian J, Manuchehri A, Healey P. Ulcerative Colitis Treatment Patterns and Cost of Care. Value Health. 2017;20:752-761. [PMID: 28577692 DOI: 10.1016/j.jval.2017.02.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
24 Vidal-Lletjós S, Beaumont M, Tomé D, Benamouzig R, Blachier F, Lan A. Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa? Nutrients 2017;9:E310. [PMID: 28335546 DOI: 10.3390/nu9030310] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
25 Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, Regueiro M, Schwartz DA, Quinn CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015;42:132-44. [PMID: 25812483 DOI: 10.1016/j.cct.2015.03.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
26 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
27 Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0463-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 19.0] [Reference Citation Analysis]
28 Leong RW, Butcher RO, Picco MF. Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitis. Gastrointest Endosc Clin N Am 2014;24:419-25. [PMID: 24975532 DOI: 10.1016/j.giec.2014.04.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
29 Patel DB, van Deen WK, Almario CV, Khalil C, Warui E, Bonthala N, Melmed GY, Spiegel BMR. Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. Inflammatory Bowel Diseases 2021;27:1593-601. [DOI: 10.1093/ibd/izaa311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Han YD, Al Bandar MH, Dulskas A, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. BMC Surg 2017;17:28. [PMID: 28327112 DOI: 10.1186/s12893-017-0224-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
31 Yang LP, Mccormack PL. MMX® Mesalazine: A Review of its Use in the Management of Mild to Moderate Ulcerative Colitis. Drugs 2011;71:221-35. [DOI: 10.2165/11205870-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
32 Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963-2969. [PMID: 23812861 DOI: 10.1007/s10620-013-2748-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
34 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
35 Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointestinal Endoscopy 2018;87:1304-9. [DOI: 10.1016/j.gie.2017.12.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
36 Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, Singh E, Sunna N, Tarcha N, Mosli M. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Expert Rev Gastroenterol Hepatol. 2018;12:883-897. [PMID: 30096985 DOI: 10.1080/17474124.2018.1503052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Choi CH, Kim Y, Kim YS, Ye BD, Lee KM, Lee BI, Jung S, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the Management of Ulcerative Colitis. Intest Res 2012;10:1. [DOI: 10.5217/ir.2012.10.1.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
38 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
39 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Yamada K, Sugawara T. Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. Perm J 2018;22:17-167. [PMID: 30005726 DOI: 10.7812/TPP/17-167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
40 Kuwahara E, Murakami Y, Nakamura T, Inoue N, Nagahori M, Matsui T, Watanabe M, Suzuki Y, Nishiwaki Y. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol 2017;52:185-93. [PMID: 27075755 DOI: 10.1007/s00535-016-1209-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
41 Gallinger ZR, Weizman AV. Colorectal cancer in inflammatory bowel disease: a shift in risk? Expert Review of Anticancer Therapy 2014;14:847-56. [DOI: 10.1586/14737140.2014.895936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
42 Kawahara H, Hiramoto Y, Takeda M, Matsumoto N, Misawa T, Yanaga K. Anthropometric Assessment After Proctocolectomy Due to Ulcerative Colitis. In Vivo 2019;33:239-43. [PMID: 30587630 DOI: 10.21873/invivo.11466] [Reference Citation Analysis]
43 Rubin DT, Mody R, Davis KL, Wang C. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 2014;39:1143-55. [DOI: 10.1111/apt.12727] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
44 Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374-381. [PMID: 24961751 DOI: 10.1111/apt.12834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
45 Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71:1285-99. [PMID: 31436026 DOI: 10.1002/acr.24025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 21.5] [Reference Citation Analysis]
46 Singh S, Chowdhry M, Umar S, Bilal M, Clarke K. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf) 2018;6:61-4. [PMID: 29479445 DOI: 10.1093/gastro/gox005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
47 Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol 2020;20:18. [PMID: 31964359 DOI: 10.1186/s12876-020-1164-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
48 Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. Postgrad Med 2018;130:355-60. [PMID: 29460659 DOI: 10.1080/00325481.2018.1442978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
50 Emoto S, Nozawa H, Kawai K, Hata K, Tanaka T, Shuno Y, Nishikawa T, Sasaki K, Kaneko M, Hiyoshi M, Murono K, Ishihara S. Venous thromboembolism in colorectal surgery: Incidence, risk factors, and prophylaxis. Asian J Surg 2019;42:863-73. [PMID: 30683604 DOI: 10.1016/j.asjsur.2018.12.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
51 Oustamanolakis P, Koutroubakis IE. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance: . Inflammatory Bowel Diseases 2011;17:E8-9. [DOI: 10.1002/ibd.21323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
52 Rao K, Higgins PD. Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1744-54. [PMID: 27120571 DOI: 10.1097/MIB.0000000000000793] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 11.3] [Reference Citation Analysis]
53 Krishnarao A, de Leon L, Bright R, Moniz H, Law M, Leleiko N, Sands BE, Merrick M, Shapiro J, Wallenstein S. Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamm Bowel Dis. 2015;21:564-569. [PMID: 25581825 DOI: 10.1097/mib.0000000000000309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
54 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
55 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-1619. [PMID: 22914296 DOI: 10.1016/s0140-6736(12)60150-0] [Cited by in Crossref: 840] [Cited by in F6Publishing: 408] [Article Influence: 93.3] [Reference Citation Analysis]
57 Kushkevych I, Kollar P, Ferreira AL, Palma D, Duarte A, Lopes MM, Bartos M, Pauk K, Imramovsky A, Jampilek J. Antimicrobial effect of salicylamide derivatives against intestinal sulfate-reducing bacteria. J Appl Biomed 2016;14:125-30. [DOI: 10.1016/j.jab.2016.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
58 Li J, Tian H, Jiang HJ, Han B. Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: A meta-analysis. World J Gastroenterol 2014; 20(42): 15899-15909 [PMID: 25400476 DOI: 10.3748/wjg.v20.i42.15899] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
59 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 13.5] [Reference Citation Analysis]
60 Windsor A, Michetti P, Bemelman W, Ghosh S. The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis. 2013;19:2695-2703. [PMID: 23846487 DOI: 10.1097/mib.0b013e318292fae6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
61 Wanes D, Jabri MA, Tounsi H, Rtibi K, Zouari N, Hajji N, Jridi M, Abdellaoui A, Sebai H. Chemical Characterization of Bioactive Components of Rosa canina Extract and Its Protective Effect on Dextran Sulfate Sodium-Induced Intestinal Bowel Disease in a Mouse Model. J Med Food 2020;23:1109-19. [PMID: 32379993 DOI: 10.1089/jmf.2019.0191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Chapman CG, Rubin DT. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2014;24:353-65. [PMID: 24975527 DOI: 10.1016/j.giec.2014.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
63 Nett A, Velayos F, McQuaid K. Quality bowel preparation for surveillance colonoscopy in patients with inflammatory bowel disease is a must. Gastrointest Endosc Clin N Am. 2014;24:379-392. [PMID: 24975529 DOI: 10.1016/j.giec.2014.03.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
64 Zhang S, Ermann J, Succi MD, Zhou A, Hamilton MJ, Cao B, Korzenik JR, Glickman JN, Vemula PK, Glimcher LH, Traverso G, Langer R, Karp JM. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci Transl Med 2015;7:300ra128. [PMID: 26268315 DOI: 10.1126/scitranslmed.aaa5657] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 30.8] [Reference Citation Analysis]
65 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
66 Alrubaiy L, Rikaby I, Dodds P, Hutchings HA, Williams JG. Systematic review of health-related quality of life measures for inflammatory bowel disease. J Crohns Colitis. 2015;9:284-292. [PMID: 25576752 DOI: 10.1093/ecco-jcc/jjv002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
67 Stawowczyk E, Kawalec P. Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review. Prz Gastroenterol 2017;12:90-7. [PMID: 28702096 DOI: 10.5114/pg.2017.68166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Hotta S, Shimada Y, Nakano M, Yamada S, Abe K, Oyanagi H, Yagi R, Tajima Y, Nakano M, Kameyama H, Nagahashi M, Sakata J, Kobayashi T, Wakai T. Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: A retrospective study. Asian J Surg 2019;42:267-73. [PMID: 29454571 DOI: 10.1016/j.asjsur.2018.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Buchner AM, Lichtenstein GR. Evaluation and Detection of Dysplasia in IBD: the Role of Chromoendoscopy and Enhanced Imaging Techniques. Curr Treat Options Gastro 2016;14:73-82. [DOI: 10.1007/s11938-016-0078-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
70 Moura FA, de Andrade KQ, Dos Santos JCF, Araújo ORP, Goulart MOF. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol 2015;6:617-39. [PMID: 26520808 DOI: 10.1016/j.redox.2015.10.006] [Cited by in Crossref: 175] [Cited by in F6Publishing: 158] [Article Influence: 29.2] [Reference Citation Analysis]
71 Winkelmann P, Unterweger AL, Khullar D, Beigel F, Koletzko L, Siebeck M, Gropp R. The PI3K pathway as a therapeutic intervention point in inflammatory bowel disease. Immun Inflamm Dis 2021;9:804-18. [PMID: 33942546 DOI: 10.1002/iid3.435] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Kim CN. A Common Complication After an Ileal Pouch-Anal Anastomosis With a Loop Ileostomy in Patients With Ulcerative Colitis: Small Bowel Obstruction. Ann Coloproctol. 2018;34:57-58. [PMID: 29742857 DOI: 10.3393/ac.2017.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
74 Andújar I, Ríos JL, Giner RM, Miguel Cerdá J, Recio Mdel C. Beneficial effect of shikonin on experimental colitis induced by dextran sulfate sodium in BALB/c mice. Evid Based Complement Alternat Med 2012;2012:271606. [PMID: 23346196 DOI: 10.1155/2012/271606] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
75 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
76 Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol 2015; 21(15): 4457-4465 [PMID: 25914455 DOI: 10.3748/wjg.v21.i15.4457] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
77 Zammarchi I, Lanzarotto F, Cannatelli R, Munari F, Benini F, Pozzi A, Lanzini A, Ricci C. Elderly-onset vs adult-onset ulcerative colitis: a different natural history? BMC Gastroenterol 2020;20:147. [PMID: 32398011 DOI: 10.1186/s12876-020-01296-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128:273-281. [PMID: 26861051 DOI: 10.1080/00325481.2016.1152876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
79 Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11:785-791. [PMID: 28333362 DOI: 10.1093/ecco-jcc/jjx032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
80 Nagao-Kitamoto H, Kamada N. Host-microbial Cross-talk in Inflammatory Bowel Disease. Immune Netw 2017;17:1-12. [PMID: 28261015 DOI: 10.4110/in.2017.17.1.1] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 17.8] [Reference Citation Analysis]
81 Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011;34:747-756. [PMID: 21848857 DOI: 10.1111/j.1365-2036.2011.04800.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
82 Friedman S. Sexual Dysfunction in Inflammatory Bowel Disease: “Donʼt Ask, Donʼt Tell” Doesnʼt Work. Inflammatory Bowel Diseases 2015;21:948-50. [DOI: 10.1097/mib.0000000000000259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
83 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
84 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
85 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
86 Etienne D, Ofosu A, Ona MA, Reddy M. Microcarcinoid and Ulcerative Colitis: Case Report and Literature Review. Cureus 2020;12:e8803. [PMID: 32724749 DOI: 10.7759/cureus.8803] [Reference Citation Analysis]
87 Cotter TG, Gathaiya N, Catania J, Loftus EV Jr, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol 2017;15:850-6. [PMID: 28013116 DOI: 10.1016/j.cgh.2016.11.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
88 Kaltenbach TR, Soetikno RM, Devivo R, Laine LA, Barkun A, Mcquaid KR, Cheifetz A, Chiorean M, East JE, Farraye FA, Leighton JA, Levesque BG, Lichtenstein GR, Marion JF, Matsumoto T, Mönkemüller K, Picco MF, Odze R, Raju GS, Rutter M, Rex DK, Shen B, Shergill A, Subramanian V. Optimizing the quality of endoscopy in inflammatory bowel disease: focus on surveillance and management of colorectal dysplasia using interactive image- and video-based teaching. Gastrointestinal Endoscopy 2017;86:1107-1117.e1. [DOI: 10.1016/j.gie.2017.07.045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
89 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
90 Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882 [PMID: 31636478 DOI: 10.3748/wjg.v25.i38.5862] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
91 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
92 Xu J, Tam M, Samaei S, Lerouge S, Barralet J, Stevenson MM, Cerruti M. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater 2017;48:247-57. [PMID: 27769943 DOI: 10.1016/j.actbio.2016.10.026] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 13.8] [Reference Citation Analysis]
93 Virta LJ, Kolho KL. Trends in early outpatient drug therapy in pediatric inflammatory bowel disease in Finland: a nationwide register-based study in 1999-2009. ISRN Gastroenterol 2012;2012:462642. [PMID: 22957263 DOI: 10.5402/2012/462642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
94 Richter JM, Arshi NK, Oster G. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Can J Gastroenterol Hepatol 2016;2016:6928710. [PMID: 27446860 DOI: 10.1155/2016/6928710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
95 Je IG, Lee DG, Jeong DG, Hong D, Yoon JM, Moon JS, Park S. The Probiotic, ID-JPL934, Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice Through Inhibition of Proinflammatory Cytokines Expression. J Med Food 2018;21:858-65. [PMID: 30036104 DOI: 10.1089/jmf.2017.4152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
96 Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112:241-258. [PMID: 28071656 DOI: 10.1038/ajg.2016.537] [Cited by in Crossref: 218] [Cited by in F6Publishing: 176] [Article Influence: 54.5] [Reference Citation Analysis]
97 Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol 2019;114:472-82. [PMID: 30410041 DOI: 10.1038/s41395-018-0272-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 26.5] [Reference Citation Analysis]
98 Chande N. Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:669-671. [PMID: 23385239 DOI: 10.1097/mib.0b013e31827e7a0f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
99 Fornaro R, Caratto M, Caratto E, Caristo G, Fornaro F, Giovinazzo D, Sticchi C, Casaccia M, Andorno E. Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program. Clin Colorectal Cancer 2016;15:204-12. [PMID: 27083409 DOI: 10.1016/j.clcc.2016.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
100 Mao TY, Shi R, Zhao WH, Guo Y, Gao KL, Chen C, Xie TH, Li JX. Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response. Evid Based Complement Alternat Med 2016;2016:4312538. [PMID: 27413386 DOI: 10.1155/2016/4312538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
101 Li H, Gong Y, Xie Y, Sun Q, Li Y. Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis. Scandinavian Journal of Gastroenterology 2018;53:1031-42. [DOI: 10.1080/00365521.2016.1192678] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
102 Neumann PA, Rijcken E. Minimally invasive surgery for inflammatory bowel disease: Review of current developments and future perspectives. World J Gastrointest Pharmacol Ther 2016; 7(2): 217-226 [PMID: 27158537 DOI: 10.4292/wjgpt.v7.i2.217] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
103 Cole EB, Shah Y, McLean LP, Yang YX, Khan N. Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal Cancer. Clin Colorectal Cancer 2018;17:e289-92. [PMID: 29398423 DOI: 10.1016/j.clcc.2018.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
104 Al-Sukhni W, McLeod RS, MacRae H, O’Connor B, Huang H, Cohen Z. Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. Dis Colon Rectum. 2010;53:1495-1500. [PMID: 20940597 DOI: 10.1007/dcr.0b013e3181f222d5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
105 Nguyen GC, Devlin SM, Afif W, Bressler B, Gruchy SE, Kaplan GG, Oliveira L, Plamondon S, Seow CH, Williams C. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285. [PMID: 24839622 DOI: 10.1155/2014/941245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
106 Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. Br J Clin Pharmacol 2021;87:1141-9. [PMID: 32671846 DOI: 10.1111/bcp.14479] [Reference Citation Analysis]
107 Mckie K, Mcloughlin RJ, Hirsh MP, Cleary MA, Aidlen JT. Risk Factors for Venous Thromboembolism in Children and Young Adults With Inflammatory Bowel Disease. Journal of Surgical Research 2019;243:173-9. [DOI: 10.1016/j.jss.2019.04.087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
108 Walker L, Yip V, Pirmohamed M. Adverse Drug Reactions. Handbook of Pharmacogenomics and Stratified Medicine. Elsevier; 2014. pp. 405-35. [DOI: 10.1016/b978-0-12-386882-4.00020-7] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
109 Ge X, Jiang L, Yu W, Wu Y, Liu W, Qi W, Cao Q, Bai R, Zhou W. The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. Dig Liver Dis 2021;53:965-71. [PMID: 33934998 DOI: 10.1016/j.dld.2021.03.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chen YM, Deng JM, Wen Y, Chen B, Hou JT, Peng B, Zhang SJ, Mi H, Jiang QL, Wu XL, Liu FB, Chen XL. Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials. Trials 2020;21:396. [PMID: 32398112 DOI: 10.1186/s13063-020-04315-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
112 Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol 2012;12:108. [PMID: 22894661 DOI: 10.1186/1471-230X-12-108] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
113 Liu M, Xie W, Wan X, Deng T. Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis. Exp Ther Med 2020;20:10. [PMID: 32934675 DOI: 10.3892/etm.2020.9138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
114 Weber NK, Bruining DH, Loftus EV, Tremaine WJ, Augustin JJ, Becker BD, Kammer PP, Harmsen WS, Zinsmeister AR, Pardi DS. Comparative Outcomes of Younger and Older Hospitalized Patients with Inflammatory Bowel Disease Treated with Corticosteroids: . Inflammatory Bowel Diseases 2013;19:2644-51. [DOI: 10.1097/01.mib.0000436961.08029.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
115 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75:879-886. [PMID: 25920500 DOI: 10.1007/s40265-015-0396-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
116 Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, Texakalidis PT, Economopoulos KP, Kousoulis AA. Emerging treatments for ulcerative colitis: a systematic review. Scand J Gastroenterol 2017;52:923-31. [PMID: 28503977 DOI: 10.1080/00365521.2017.1326163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
117 Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis. 2016;48:726-733. [PMID: 27158125 DOI: 10.1016/j.dld.2016.03.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
118 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 19.3] [Reference Citation Analysis]
119 Ha CY, Katz S. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2014;11:128-138. [PMID: 24345890 DOI: 10.1038/nrgastro.2013.241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
120 Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis 2015;6:224-33. [PMID: 26336591 DOI: 10.1177/2040622315586970] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
121 Stawowczyk E, Kawalec P, Pilc A. Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland. Eur J Clin Pharmacol 2016;72:1319-25. [PMID: 27497991 DOI: 10.1007/s00228-016-2103-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 380] [Article Influence: 166.0] [Reference Citation Analysis]
123 Gupta S, Shen B. Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. Gastroenterol Rep (Oxf). 2013;1:159-165. [PMID: 24759961 DOI: 10.1093/gastro/got030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
124 Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. J Crohns Colitis 2017;11:335-41. [PMID: 27647858 DOI: 10.1093/ecco-jcc/jjw159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
125 Venkatesh PG, Jegadeesan R, Gutierrez NG, Sanaka MR, Navaneethan U. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis. 2013;7:968-973. [PMID: 23433613 DOI: 10.1016/j.crohns.2013.02.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
126 Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflamm Bowel Dis 2020;26:941-8. [PMID: 31560046 DOI: 10.1093/ibd/izz204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Taleban S, Elquza E, Gower-rousseau C, Peyrin-biroulet L. Cancer and inflammatory bowel disease in the elderly. Digestive and Liver Disease 2016;48:1105-11. [DOI: 10.1016/j.dld.2016.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
128 Kawalec P, Stawowczyk E. Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. Prz Gastroenterol 2018;13:61-8. [PMID: 29657613 DOI: 10.5114/pg.2018.74568] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
129 Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. J Med Econ. 2019;22:859-868. [PMID: 31012362 DOI: 10.1080/13696998.2019.1609481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
130 Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46:46-56. [PMID: 20878425 DOI: 10.1007/s00535-010-0308-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
131 Bohl JL, Sobba K. Indications and Options for Surgery in Ulcerative Colitis. Surgical Clinics of North America 2015;95:1211-32. [DOI: 10.1016/j.suc.2015.07.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
132 Song F, Zhang Y, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol 2021;192:114691. [PMID: 34293286 DOI: 10.1016/j.bcp.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Chien KA, Hammad HT, Gerber L, Sheth S, Sockolow R, Kucine N. Pediatric Gastroenterologists' Approach to Venous Thromboembolism Prophylaxis in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2018;66:286-8. [PMID: 28742719 DOI: 10.1097/MPG.0000000000001690] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Park E, Kim H, Jung SM, Sung Y, Baek HJ, Lee J. The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. J Rheum Dis 2020;27:4. [DOI: 10.4078/jrd.2020.27.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
135 Wan J, Zhang Q, Liang SH, Zhong J, Li JN, Ran ZH, Zhi FC, Wang XD, Zhang XL, Wen ZH, Sheng JQ, Shi HX, Mei Q, Wu KC. Chromoendoscopy with targeted biopsies is superior to white-light endoscopy for the long-term follow-up detection of dysplasia in ulcerative colitis patients: a multicenter randomized-controlled trial. Gastroenterol Rep (Oxf) 2021;9:14-21. [PMID: 33747522 DOI: 10.1093/gastro/goaa028] [Reference Citation Analysis]
136 Hahn L, Beggs A, Wahaib K, Kodali L, Kirkwood V. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Am J Health Syst Pharm 2015;72:1271-8. [PMID: 26195652 DOI: 10.2146/ajhp140449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
137 Zahouani Y, Ben Rhouma K, Kacem K, Sebai H, Sakly M. Aqueous Leaf Extract of Pistacia lentiscus Improves Acute Acetic Acid-Induced Colitis in Rats by Reducing Inflammation and Oxidative Stress. J Med Food 2021;24:697-708. [PMID: 33156733 DOI: 10.1089/jmf.2020.0020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; Grupo Espa˜nol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol 2013;36:104-14. [PMID: 23332546 DOI: 10.1016/j.gastrohep.2012.09.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
139 Popa P, Gheonea DI, Săftoiu A, Calița M. No Interval Cancers in Endoscopic Practice. Curr Health Sci J 2019;45:5-18. [PMID: 31297257 DOI: 10.12865/CHSJ.45.01.01] [Reference Citation Analysis]
140 Kim S, Lee B, Zhang X, Park J, Lee S, Lee H. Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. European Journal of Integrative Medicine 2017;12:12-22. [DOI: 10.1016/j.eujim.2017.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
142 Murthy SK, Kiesslich R. Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. Gastrointest Endosc. 2013;77:351-359. [PMID: 23317581 DOI: 10.1016/j.gie.2012.11.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
143 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol 2019;10:212. [PMID: 30930775 DOI: 10.3389/fphar.2019.00212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 20.5] [Reference Citation Analysis]
144 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
145 Koczka CP, Abramowitz M, Goodman AJ. The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24:759-61. [PMID: 22672925 DOI: 10.1097/MEG.0b013e3283534b2a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol 2016;9:125-30. [PMID: 27274301 DOI: 10.2147/CEG.S80237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
147 Nakase H, Herfarth H. Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences. Inflamm Intest Dis 2016;1:15-23. [PMID: 27243020 DOI: 10.1159/000443198] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
148 Sura SP, Ahmed A, Cheifetz AS, Moss AC. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol 2014;48:351-5. [PMID: 24492405 DOI: 10.1097/MCG.0000000000000083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol 2016;13:550-65. [PMID: 27071351 DOI: 10.1038/nrclinonc.2016.50] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
150 Nguyen GC, Sharma S. Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm Bowel Dis. 2013;19:2182-2189. [PMID: 23883960 DOI: 10.1097/mib.0b013e31829c01ef] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
151 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
152 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
153 Marcelino MY, Fuoco NL, Quaglio AEV, de Camargo Bittencourt RA, Garms BC, da Motta Conceição TH, Stasi LCD, Ribeiro-paes JT. Cell therapy in experimental model of inflammatory bowel disease. Journal of Coloproctology 2021;35:020-7. [DOI: 10.1016/j.jcol.2014.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
154 Kobayashi K, Tomita H, Shimizu M, Tanaka T, Suzui N, Miyazaki T, Hara A. p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer. Int J Mol Sci 2017;18:E1284. [PMID: 28621756 DOI: 10.3390/ijms18061284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
155 Papa A, Papa V, Marzo M, Scaldaferri F, Sofo L, Rapaccini GL, Danese S, Gasbarrini A. Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. Inflamm Bowel Dis. 2015;21:1204-1213. [PMID: 25581834 DOI: 10.1097/MIB.0000000000000310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
156 Zallot C, Billioud V, Frimat L, Faure P, Peyrin-Biroulet L; CREGG (Club de Reflexion des cabinets et Groupes d'Hépato-Gastroentérologie). 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. J Crohns Colitis 2013;7:551-5. [PMID: 22999780 DOI: 10.1016/j.crohns.2012.08.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
157 De Felice KM, Novotna M, Enders FT, Faubion WA, Tremaine WJ, Kantarci OH, Raffals LE. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther 2015;41:99-107. [PMID: 25348720 DOI: 10.1111/apt.12997] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
158 Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
159 Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther. 2012;36:569-574. [PMID: 22779779 DOI: 10.1111/j.1365-2036.2012.05217.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
160 Wang YR, Cangemi JR, Loftus EV, Picco MF. Rate of early/missed colorectal cancers after colonoscopy in older patients with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444-449. [PMID: 23295277 DOI: 10.1038/ajg.2012.429] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
161 Jiang XL, Wang HH, Cui HF. Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study. Med Sci Monit 2015;21:163-70. [PMID: 25582578 DOI: 10.12659/MSM.891400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG 2nd, Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality indicators for colonoscopy. Am J Gastroenterol. 2015;110:72-90. [PMID: 25448873 DOI: 10.1038/ajg.2014.385] [Cited by in Crossref: 240] [Cited by in F6Publishing: 212] [Article Influence: 34.3] [Reference Citation Analysis]
163 Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010;6:957-66. [PMID: 20979559 DOI: 10.1586/eci.10.74] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
164 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
165 Shah SA, Rubin DT, Farraye FA. Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014;16:407. [PMID: 25113042 DOI: 10.1007/s11894-014-0407-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
166 Meyer C, Bowers A, Heavener TE, Checketts JX, Vassar M. From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. Indian J Gastroenterol 2019;38:247-62. [PMID: 31270778 DOI: 10.1007/s12664-019-00965-4] [Reference Citation Analysis]
167 Shah SC, Itzkowitz SH. Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era. Gastrointest Endosc Clin N Am 2019;29:531-48. [PMID: 31078251 DOI: 10.1016/j.giec.2019.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Wenzl HH. Diarrhea in chronic inflammatory bowel diseases. Gastroenterol Clin North Am 2012;41:651-75. [PMID: 22917170 DOI: 10.1016/j.gtc.2012.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
169 Suzuki S, Takai-Igarashi T, Fukuoka Y, Wall DP, Tanaka H, Tonellato PJ. Systems analysis of inflammatory bowel disease based on comprehensive gene information. BMC Med Genet 2012;13:25. [PMID: 22480395 DOI: 10.1186/1471-2350-13-25] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
170 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
171 Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol 2012;5:113-23. [PMID: 22390554 DOI: 10.1586/ecp.12.2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
172 Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ. Physical activity and quality of life of patients with inflammatory bowel disease. Medicine (Baltimore) 2021;100:e26290. [PMID: 34232167 DOI: 10.1097/MD.0000000000026290] [Reference Citation Analysis]
173 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
174 Butter M, Weiler S, Biedermann L, Scharl M, Rogler G, Bischoff-ferrari HA, Misselwitz B. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas 2018;110:71-8. [DOI: 10.1016/j.maturitas.2018.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
175 Ha CY. Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. Clin Geriatr Med 2014;30:67-78. [PMID: 24267603 DOI: 10.1016/j.cger.2013.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
176 Khan N, Patel D, Shah Y, Lichtenstein G, Yang Y. A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:991-7. [DOI: 10.1097/mib.0000000000001080] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
177 Krease M, Stroup J, Som M, Shepard B. Fulminant ulcerative colitis complicated by treatment-refractory bacteremia. Proc (Bayl Univ Med Cent) 2016;29:407-8. [PMID: 27695178 DOI: 10.1080/08998280.2016.11929489] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
179 Jacobson BC, Giovannucci EL, Fuchs CS. Smoking and Barrett's esophagus in women who undergo upper endoscopy. Dig Dis Sci 2011;56:1707-17. [PMID: 21448698 DOI: 10.1007/s10620-011-1672-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
180 Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am. 2012;41:443-462. [PMID: 22500528 DOI: 10.1016/j.gtc.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
181 Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 2014; 20(38): 13863-13878 [PMID: 25320522 DOI: 10.3748/wjg.v20.i38.13863] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
182 Katz S. My treatment approach to the management of ulcerative colitis. Mayo Clin Proc. 2013;88:841-853. [PMID: 23910410 DOI: 10.1016/j.mayocp.2013.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol 2019;53:e1-e11. [PMID: 28737645 DOI: 10.1097/MCG.0000000000000865] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 17.0] [Reference Citation Analysis]
184 Akkol EK, Karpuz B, Sobarzo-Sánchez E, Khan H. A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. Food Chem Toxicol 2020;144:111628. [PMID: 32738379 DOI: 10.1016/j.fct.2020.111628] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Hashash JG, Chintamaneni P, Ramos Rivers CM, Koutroubakis IE, Regueiro MD, Baidoo L, Swoger JM, Barrie A, Schwartz M, Dunn MA, Binion DG. Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4-year Prospective Study. Inflamm Bowel Dis 2015;21:2576-82. [PMID: 26296061 DOI: 10.1097/MIB.0000000000000534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
186 Axelrad JE, Faye A, Slaughter JC, Harpaz N, Itzkowitz SH, Shah SC. Colorectal Strictures in Patients With Inflammatory Bowel Disease Do Not Independently Predict Colorectal Neoplasia. Inflamm Bowel Dis 2021:izab177. [PMID: 34319381 DOI: 10.1093/ibd/izab177] [Reference Citation Analysis]
187 Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PLoS One 2016;11:e0160444. [PMID: 27494322 DOI: 10.1371/journal.pone.0160444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
188 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
189 Kim MJ, Kim E, Kang B, Choe YH. Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. Yonsei Med J 2021;62:608-14. [PMID: 34164958 DOI: 10.3349/ymj.2021.62.7.608] [Reference Citation Analysis]
190 Laroui H, Sitaraman SV, Merlin D. Gastrointestinal Delivery of Anti-inflammatory Nanoparticles. Nanomedicine - Infectious Diseases, Immunotherapy, Diagnostics, Antifibrotics, Toxicology and Gene Medicine. Elsevier; 2012. pp. 101-25. [DOI: 10.1016/b978-0-12-391858-1.00006-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
191 Uranga JA, López-Miranda V, Lombó F, Abalo R. Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. Pharmacol Rep 2016;68:816-26. [PMID: 27267792 DOI: 10.1016/j.pharep.2016.05.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 15.8] [Reference Citation Analysis]
192 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
193 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 10.5] [Reference Citation Analysis]
194 Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
195 Piodi LP, Poloni A, Ulivieri FM. Managing osteoporosis in ulcerative colitis: Something new? World J Gastroenterol 2014; 20(39): 14087-14098 [PMID: 25339798 DOI: 10.3748/wjg.v20.i39.14087] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
196 Negrón ME, Kaplan GG, Barkema HW, Eksteen B, Clement F, Manns BJ, Coward S, Panaccione R, Ghosh S, Heitman SJ. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. Inflamm Bowel Dis 2014;20:2046-55. [PMID: 25230162 DOI: 10.1097/MIB.0000000000000181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
197 Mbachi C, Attar B, Oyenubi O, Yuchen W, Efesomwan A, Paintsil I, Madhu M, Ajiboye O, Simons-Linares CR, Trick WE, Kotwal V. Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study. Medicine (Baltimore) 2019;98:e16551. [PMID: 31393356 DOI: 10.1097/MD.0000000000016551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
198 Goldstone RN, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease.Surg Clin North Am. 2019;99:1141-1150. [PMID: 31676053 DOI: 10.1016/j.suc.2019.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
199 Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V. Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res 2018;16:69-74. [PMID: 29422800 DOI: 10.5217/ir.2018.16.1.69] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
200 Takeyama H, Mizushima T, Nakajima K, Uemura M, Haraguchi N, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y, Mori M. Metachronous, colitis-associated rectal cancer that developed after sporadic adenocarcinoma in an adenoma in a patient with longstanding Crohn's disease: a case report. World J Surg Oncol 2013;11:295. [PMID: 24245540 DOI: 10.1186/1477-7819-11-295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:139-147. [PMID: 30012431 DOI: 10.1016/j.cgh.2018.07.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 22.3] [Reference Citation Analysis]
202 Silva BCD, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol 2014; 20(28): 9458-9467 [PMID: 25071340 DOI: 10.3748/wjg.v20.i28.9458] [Cited by in CrossRef: 116] [Cited by in F6Publishing: 94] [Article Influence: 16.6] [Reference Citation Analysis]
203 Rameshshanker R, Wilson A. Electronic Imaging in Colonoscopy: Clinical Applications and Future Prospects. Curr Treat Options Gastroenterol. 2016;14:140-151. [PMID: 26923476 DOI: 10.1007/s11938-016-0075-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
204 Hanada Y, Khanna S, Loftus EV, Raffals LE, Pardi DS. Non– Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:528-33. [DOI: 10.1016/j.cgh.2017.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
205 Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465. [PMID: 29205421 DOI: 10.1111/apt.14449] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 18.8] [Reference Citation Analysis]
206 D'haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016;44:1018-29. [DOI: 10.1111/apt.13803] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
207 Ehrlich AC, Patel S, Meillier A, Rothstein RD, Friedenberg FK. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther 2017;17:247-55. [PMID: 28095263 DOI: 10.1080/14737140.2017.1283987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
208 Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis 2021;15:1130-41. [PMID: 33290538 DOI: 10.1093/ecco-jcc/jjaa249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
210 Huang LC, Merchea A. Dysplasia and Cancer in Inflammatory Bowel Disease. Surgical Clinics of North America 2017;97:627-39. [DOI: 10.1016/j.suc.2017.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
211 Patel N, Suarez LD, Kapur S, Bielory L. Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature. Case Reports Immunol 2015;2015:925861. [PMID: 26339513 DOI: 10.1155/2015/925861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
212 Germer C, Isbert C. Operative Therapie chronisch-entzündlicher Darmerkrankungen: Indikationen und Stellenwert. Internist 2014;55:918-24. [DOI: 10.1007/s00108-013-3444-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Lee KH, Choi CH. [The effect of probiotics in ulcerative colitis]. Korean J Gastroenterol 2012;60:67-70. [PMID: 23094275 DOI: 10.4166/kjg.2012.60.2.67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;38:255-263. [PMID: 23730956 DOI: 10.1111/apt.12366] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 9.8] [Reference Citation Analysis]
215 Kane S. Preparing the Patient for Immunosuppressive Therapy. Curr Gastroenterol Rep 2010;12:502-6. [DOI: 10.1007/s11894-010-0142-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
216 Hillock NT, Heard S, Kichenadasse G, Hill CL, Andrews J. Infliximab for ipilimumab-induced colitis: A series of 13 patients. Asia-Pac J Clin Oncol 2017;13:e284-90. [DOI: 10.1111/ajco.12651] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
217 Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034-2042. [PMID: 22294550 DOI: 10.1002/ibd.22901] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
218 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 37.2] [Reference Citation Analysis]
219 Zhang C, Krishna SG, Hinton A, Arsenescu R, Levine EJ, Conwell DL. Cytomegalovirus-Related Hospitalization Is Associated With Adverse Outcomes and Increased Health-Care Resource Utilization in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2016;7:e150. [PMID: 26963000 DOI: 10.1038/ctg.2016.10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
220 Cao Y, Zhang B, Wu Y, Wang Q, Wang J, Shen F. The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5480961. [PMID: 29849592 DOI: 10.1155/2018/5480961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
221 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
222 Rubin DT, Hanauer SB, Lichtenstein GR, Mcgovern DPB, Regueiro MD, Snapper S, Targan S. Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. Am J Gastroenterol Suppl 2016;3:4-7. [DOI: 10.1038/ajgsup.2016.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
223 Rottenstreich A, Diminsky M, Granovsky SG, Mishael T, Roth B, Spectre G, Kalish Y, Goldin E, Shitrit AB. Assessment of the procoagulant potential and associated risk factors in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2019;65:63-8. [PMID: 31036438 DOI: 10.1016/j.ejim.2019.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG, Kupcinskas L, Lesniakowski K, Grinevich VB, Malecka-Panas E, Ardizzone S, D'Arienzo A, Valpiani D, Koch M, Denapiene G, Vago G, Fociani P, Zerbi P, Ceracchi M, Camerini R, Gasbarrini G. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther 2011;34:1088-97. [PMID: 21929562 DOI: 10.1111/j.1365-2036.2011.04844.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
225 Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-1226.e1-2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 133] [Article Influence: 16.4] [Reference Citation Analysis]
226 Ten Hove JR, Mooiweer E, Dekker E, van der Meulen-de Jong AE, Offerhaus GJ, Ponsioen CY, Siersema PD, Oldenburg B. Low Rate of Dysplasia Detection in Mucosa Surrounding Dysplastic Lesions in Patients Undergoing Surveillance for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2017;15:222-228.e2. [PMID: 27613257 DOI: 10.1016/j.cgh.2016.08.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
227 Ho SL, Niu F, Pola S, Velayos FS, Ning X, Hui RL. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. BioDrugs 2020;34:395-404. [PMID: 32103457 DOI: 10.1007/s40259-020-00409-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
228 Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16 Suppl 1:S1-S11. [PMID: 21104734 DOI: 10.1002/ibd.21529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
229 Taleban S. Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastro 2015;13:275-86. [DOI: 10.1007/s11938-015-0059-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
230 Chu BK, Scott FI, Bewtra M. Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. J Gastrointest Surg 2021. [PMID: 34725785 DOI: 10.1007/s11605-021-05180-1] [Reference Citation Analysis]
231 Faye AS, Hung KW, Cheng K, Blackett JW, Mckenney AS, Pont AR, Li J, Lawlor G, Lebwohl B, Freedberg DE. Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;. [PMID: 31689354 DOI: 10.1093/ibd/izz269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
232 Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 2015;41:409-18. [PMID: 25588902 DOI: 10.1111/apt.13076] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
233 Hudesman DP, Chakravarty SD, Emond B, Ellis LA, Lefebvre P, Sadik K, Scher JU. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. BMC Rheumatol 2020;4:16. [PMID: 32266326 DOI: 10.1186/s41927-020-0115-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
234 Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1095-1113. [PMID: 23662785 DOI: 10.1111/jgh.12260] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
235 Rosenberg L, Lawlor GO, Zenlea T, Goldsmith JD, Gifford A, Falchuk KR, Wolf JL, Cheifetz AS, Robson SC, Moss AC. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779-784. [PMID: 23446338 DOI: 10.1097/mib.0b013e3182802b0e] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
236 Li N, Zhang Y, Nepal N, Li G, Yang N, Chen H, Lin Q, Ji X, Zhang S, Jin S. Dental pulp stem cells overexpressing hepatocyte growth factor facilitate the repair of DSS-induced ulcerative colitis. Stem Cell Res Ther 2021;12:30. [PMID: 33413675 DOI: 10.1186/s13287-020-02098-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database. Dig Dis Sci 2011;56:3463-70. [DOI: 10.1007/s10620-011-1877-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
238 Katsanos AH, Katsanos KH, Kosmidou M, Giannopoulos S, Kyritsis AP, Tsianos EV. Cerebral sinus venous thrombosis in inflammatory bowel diseases. QJM. 2013;106:401-413. [PMID: 23243293 DOI: 10.1093/qjmed/hcs229] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
239 El-bassat H, Aboali L, El Yamany S, Al Shenawy H, Al Din RA, Taha A. Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. Advances in Digestive Medicine 2016;3:88-94. [DOI: 10.1016/j.aidm.2015.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
240 Bartel MJ, Picco MF, Wallace MB. Chromocolonoscopy. Gastrointest Endosc Clin N Am. 2015;25:243-260. [PMID: 25839685 DOI: 10.1016/j.giec.2014.11.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
241 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
242 Scoville EA, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Venous thromboembolism in patients with inflammatory bowel diseases: a case-control study of risk factors. Inflamm Bowel Dis. 2014;20:631-636. [PMID: 24552828 DOI: 10.1097/mib.0000000000000007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
243 Chien KA, Cooley V, Prishtina F, Grinspan ZM, Gerber LM, Kucine N. Health and Financial Burdens Associated With Venous Thrombosis in Hospitalized Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021;72:748-51. [PMID: 33616374 DOI: 10.1097/MPG.0000000000003052] [Reference Citation Analysis]
244 Kaur M, Singapura P, Kalakota N, Cruz G, Shukla R, Ahsan S, Tansel A, Thrift AP, El-serag HB. Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2018;16:1616-1621.e1. [DOI: 10.1016/j.cgh.2017.11.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
245 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 5.3] [Reference Citation Analysis]
246 Panés J, Su C, Bushmakin AG, Cappelleri JC, Healey P. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. J Crohns Colitis 2016;10:1310-5. [PMID: 27194530 DOI: 10.1093/ecco-jcc/jjw107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
247 Ahn SI, Cho S, Choi NJ. Effect of dietary probiotics on colon length in an inflammatory bowel disease-induced murine model: A meta-analysis. J Dairy Sci. 2020;103:1807-1819. [PMID: 31785874 DOI: 10.3168/jds.2019-17356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
248 Gaidos JKJ, Bickston SJ. How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients: . Inflammatory Bowel Diseases 2016;22:1219-30. [DOI: 10.1097/mib.0000000000000685] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
249 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 35.2] [Reference Citation Analysis]
250 Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians’ perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci. 2013;58:46-52. [PMID: 23053902 DOI: 10.1007/s10620-012-2435-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
251 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Reference Citation Analysis]
252 Kristensen V, Lauritzen T, Jelsness-JØrgensen LP, Moum B. Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods. Scand J Clin Lab Invest 2015;75:355-61. [PMID: 25856663 DOI: 10.3109/00365513.2015.1030765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
253 Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016; 22(3): 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 83] [Article Influence: 19.4] [Reference Citation Analysis]
254 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
255 Kobayashi M, Matsubara N, Nakachi Y, Okazaki Y, Uchino M, Ikeuchi H, Song J, Kimura K, Yasuhara M, Babaya A, Yamano T, Ikeda M, Nishikawa H, Matsuda I, Hirota S, Tomita N. Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer. In Vivo 2020;34:57-63. [PMID: 31882463 DOI: 10.21873/invivo.11745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
256 Kim M, Katz S, Green J. Drug Management in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2015;13:90-104. [PMID: 25617139 DOI: 10.1007/s11938-014-0039-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
257 Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1392-400. [PMID: 25856768 DOI: 10.1097/MIB.0000000000000391] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
258 Constantin J, Atanasov P, Wirth D, Borsi A. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterol 2019;19:179. [PMID: 31706270 DOI: 10.1186/s12876-019-1095-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
259 Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1166-74. [PMID: 30672608 DOI: 10.1111/jgh.14609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
260 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513-22. [PMID: 20676771 DOI: 10.1007/s10620-010-1334-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
261 Shergill AK, Farraye FA. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014;24:469-481. [PMID: 24975537 DOI: 10.1016/j.giec.2014.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
262 Hullah EA, Escudier MP. The mouth in inflammatory bowel disease and aspects of orofacial granulomatosis. Periodontol 2000 2019;80:61-76. [DOI: 10.1111/prd.12264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
263 Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2016;63:130-55. [DOI: 10.1097/mpg.0000000000001188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
264 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
265 Lv Y, Xu X, Zhang B, Zhou G, Li H, Du C, Han H, Wang H. Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice. J Transl Med. 2014;12:344. [PMID: 25475342 DOI: 10.1186/s12967-014-0344-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
266 Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci 2016;61:358-70. [PMID: 26541989 DOI: 10.1007/s10620-015-3897-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
267 D'haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. American Journal of Gastroenterology 2012;107:1064-77. [DOI: 10.1038/ajg.2012.103] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
268 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
269 Allen JI. Gastroenterologists and the Triple Aim: How to Become Accountable. Gastrointestinal Endoscopy Clinics of North America 2012;22:85-96. [DOI: 10.1016/j.giec.2011.08.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
270 Shah SC, Naymagon S, Panchal HJ, Sands BE, Cohen BL, Dubinsky MC. Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflamm Bowel Dis 2018;24:651-9. [PMID: 29462380 DOI: 10.1093/ibd/izx039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
271 Geyshis B, Katz G, Ben-Horin S, Kopylov U. A patient with ulcerative colitis and central serous chorioretinopathy--a therapeutic dilemma. J Crohns Colitis. 2013;7:e66-e68. [PMID: 22621790 DOI: 10.1016/j.crohns.2012.04.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
272 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
273 Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
274 Abinusawa A, Tenjarla S. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels. Adv Ther 2015;32:477-84. [PMID: 25951927 DOI: 10.1007/s12325-015-0206-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
275 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
276 Manzi SF, Fusaro VA, Chadwick L, Brownstein C, Clinton C, Mandl KD, Wolf WA, Hawkins JB. Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration - experience from a pediatric tertiary care facility. J Am Med Inform Assoc 2017;24:74-80. [PMID: 27301749 DOI: 10.1093/jamia/ocw052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
277 Gao Q, Bi P, Luo D, Guan Y, Zeng W, Xiang H, Mi Q, Yang G, Li X, Yang B. Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model. Chem Biol Interact 2020;317:108943. [PMID: 31926917 DOI: 10.1016/j.cbi.2020.108943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
278 Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
279 Tavakoli A, Shirzad M, Taghavi A, Fattahi M, Ahmadian-Attari M, Mohammad Taghizadeh L, Rostami Chaijan M, Sedigh Rahimabadi M, Akrami R, Pasalar M. Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Galen Med J 2019;8:e1307. [PMID: 34466491 DOI: 10.31661/gmj.v8i0.1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Johnston A, Natarajan S, Hayes M, MacDonald E, Shorr R. Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol. BMJ Open 2018;8:e019909. [PMID: 29382683 DOI: 10.1136/bmjopen-2017-019909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
281 Kawachi H. Histopathological diagnosis of ulcerative colitis‐associated neoplasia. Digestive Endoscopy 2019;31:31-5. [DOI: 10.1111/den.13387] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
282 Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-9. [PMID: 24582568 DOI: 10.1016/j.cgh.2014.02.026] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
283 Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. [Guidelines for the management of ulcerative colitis]. Korean J Gastroenterol. 2012;59:118-140. [PMID: 22387836 DOI: 10.4166/kjg.2012.59.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
284 Leong RW, Perry J, Campbell B, Koo J, Turner IB, Corte C, Fok IK. Knowledge and predictors of dysplasia surveillance performance in inflammatory bowel diseases in Australia. Gastrointest Endosc 2015;82:708-714.e4. [PMID: 26007222 DOI: 10.1016/j.gie.2015.04.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
285 Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med 2020;35:41-59. [PMID: 31935319 DOI: 10.3904/kjim.2019.411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
286 Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80. [PMID: 31660640 DOI: 10.1111/apt.15555] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
287 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
288 Stavsky J, Maitra R. The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. Nutr Metab Insights 2019;12:1178638819834526. [PMID: 30911221 DOI: 10.1177/1178638819834526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Ohta Y, Arai M, Nakagawa T, Akizue N, Ishikawa K, Hamanaka S, Koseki H, Taida T, Okimoto K, Saito K, Yoshihama S, Maruoka D, Matsumura T, Katsuno T, Kato N. Comparison of a novel predictor of venous thromboembolic complications in inflammatory bowel disease with current predictors. J Gastroenterol Hepatol. 2019;34:870-879. [PMID: 30225931 DOI: 10.1111/jgh.14472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
290 Dumic I, Nordin T, Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T, Milovanovic T. Gastrointestinal Tract Disorders in Older Age. Can J Gastroenterol Hepatol 2019;2019:6757524. [PMID: 30792972 DOI: 10.1155/2019/6757524] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 25.5] [Reference Citation Analysis]
291 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 9.5] [Reference Citation Analysis]
292 Axelrad JE, Shah SC. Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. Therap Adv Gastroenterol 2020;13:1756284820920779. [PMID: 32523622 DOI: 10.1177/1756284820920779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
293 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
294 Atreya R, Reinisch W, Peyrin-biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Digestive and Liver Disease 2018;50:1019-29. [DOI: 10.1016/j.dld.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
295 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 564] [Article Influence: 227.3] [Reference Citation Analysis]
296 Yu RG, Zhang JY, Liu ZT, Zhuo YG, Wang HY, Ye J, Liu N, Zhang YY. Text Mining-Based Drug Discovery in Osteoarthritis. J Healthc Eng 2021;2021:6674744. [PMID: 33953899 DOI: 10.1155/2021/6674744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 14.3] [Reference Citation Analysis]
298 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 2016;17:1339-49. [DOI: 10.1080/14656566.2016.1187132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
299 Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019;8:212572. [PMID: 31065290 DOI: 10.7573/dic.212572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
300 Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
301 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
302 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 27.3] [Reference Citation Analysis]
303 Lucena AMM, Souza CRM, Jales JT, Guedes PMM, de Miranda GEC, de Moura AMA, Araújo-Júnior JX, Nascimento GJ, Scortecci KC, Santos BVO, Souto JT. The Bisindole Alkaloid Caulerpin, from Seaweeds of the Genus Caulerpa, Attenuated Colon Damage in Murine Colitis Model. Mar Drugs 2018;16:E318. [PMID: 30205459 DOI: 10.3390/md16090318] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
304 Khan DA. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests. Journal of Allergy and Clinical Immunology 2016;138:943-55. [DOI: 10.1016/j.jaci.2016.08.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
305 何金玲, 戴彦成. 护理干预对重症溃疡性结肠炎患者术后生活质量及心理状态的影响. 世界华人消化杂志 2016; 24(15): 2415-2420 [DOI: 10.11569/wcjd.v24.i15.2415] [Reference Citation Analysis]
306 Lipka S, Katz S, Kaur N. “One more time” 5-ASA retrial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: A prospective community practice experience. Journal of Crohn's and Colitis 2013;7:342-3. [DOI: 10.1016/j.crohns.2012.07.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
307 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
308 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396 [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
309 Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014;146:110-118.e3. [PMID: 24067881 DOI: 10.1053/j.gastro.2013.09.032] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
310 Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res 2018;16:522-8. [PMID: 30321913 DOI: 10.5217/ir.2018.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
311 Hall MJ, Morris AM, Sun W. Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. Am Soc Clin Oncol Educ Book 2018;38:220-30. [PMID: 30231337 DOI: 10.1200/EDBK_200961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
312 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 原皓, 崔慎茹, 李时光. 甘草酸二铵对溃疡性结肠炎大鼠Foxp3 mRNA表达的影响. 世界华人消化杂志 2010; 18(31): 3301-3305 [DOI: 10.11569/wcjd.v18.i31.3301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Zhao X, Li N, Ren Y, Ma T, Wang C, Wang J, You S. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160500. [PMID: 27501314 DOI: 10.1371/journal.pone.0160500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
315 Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World J Gastroenterol 2017; 23(45): 8008-8016 [PMID: 29259376 DOI: 10.3748/wjg.v23.i45.8008] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
316 Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Dig Dis Sci. 2016;61:221-229. [PMID: 26563167 DOI: 10.1007/s10620-015-3866-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
317 Khan N, Cole E, Shah Y, Paulson EC. Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. Colorectal Dis 2017;19:1108-16. [PMID: 28498617 DOI: 10.1111/codi.13721] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
318 Deepak P, Hanson GJ, Fletcher JG, Tremaine WJ, Pardi DS, Kisiel JB, Schroeder KW, Wong Kee Song LM, Harmsen WS, Loftus EV, Bruining DH. Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointestinal Endoscopy 2016;83:1005-12. [DOI: 10.1016/j.gie.2015.09.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
319 Elmashad NM, Ziada DH, Hasby EA, Mohamed AEM. Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma. J Microsc Ultrastruct 2016;4:195-202. [PMID: 30023227 DOI: 10.1016/j.jmau.2016.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
320 Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol 2013;13:23. [PMID: 23363459 DOI: 10.1186/1471-230X-13-23] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
321 Ahmad H, Verma S, Kumar VL. Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis. Inflamm Res 2018;67:147-55. [PMID: 28988395 DOI: 10.1007/s00011-017-1103-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
322 Wan J, Wang X, Yang ZP, Wu KC. Systematic review with meta-analysis: Chromoendoscopy versus white light endoscopy in detection of dysplasia in patients with inflammatory bowel disease. J Dig Dis. 2019;20:206-214. [PMID: 30756472 DOI: 10.1111/1751-2980.12714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
323 Kelso M, Weideman RA, Cipher DJ, Feagins LA. Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare. Inflamm Bowel Dis 2017;24:5-11. [PMID: 29272483 DOI: 10.1093/ibd/izx020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
324 Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. [PMID: 28566467 DOI: 10.1136/bmj.j2083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
325 Häuser W, Moser G, Klose P, Mikocka-Walus A. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: A review. World J Gastroenterol 2014; 20(13): 3663-3671 [PMID: 24707152 DOI: 10.3748/wjg.v20.i13.3663] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
326 Vityazev FV, Fedyuneva MI, Golovchenko VV, Patova OA, Ipatova EU, Durnev EA, Martinson EA, Litvinets SG. Pectin-silica gels as matrices for controlled drug release in gastrointestinal tract. Carbohydrate Polymers 2017;157:9-20. [DOI: 10.1016/j.carbpol.2016.09.048] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
327 Meng WB, Li X, Li YM, Zhou WC, Zhu XL. Three initial diets for management of mild acute pancreatitis: A meta-analysis. World J Gastroenterol 2011; 17(37): 4235-4241 [PMID: 22072857 DOI: 10.3748/wjg.v17.i37.4235] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
328 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
329 Siegel CA, Yang F, Eslava S, Cai Z. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. Clin Transl Gastroenterol 2020;11:e00128. [PMID: 32463619 DOI: 10.14309/ctg.0000000000000128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
330 Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ 2018;19:229-40. [PMID: 28271250 DOI: 10.1007/s10198-017-0879-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
331 Tenjarla S. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels. Drugs R D 2015;15:211-5. [PMID: 26115756 DOI: 10.1007/s40268-015-0097-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
332 Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study. Aliment Pharmacol Ther 2018;47:596-604. [PMID: 29239001 DOI: 10.1111/apt.14466] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
333 Kane S. If variety is the spice of life, we need to rethink our recipe: variation in inflammatory bowel disease practice among tertiary centers. Clin Gastroenterol Hepatol 2015;13:1201-3. [PMID: 25638587 DOI: 10.1016/j.cgh.2015.01.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
334 Sultan K, Shah D, Bhorania K, Zhou E, Khan S, Kohn N, Qiu M, Spyropoulos A. Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. Dig Dis Sci 2019;64:3256-62. [DOI: 10.1007/s10620-019-05650-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
335 Tinsley A, Naymagon S, Enomoto LM, Hollenbeak CS, Sands BE, Ullman TA. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis. 2013;7:e635-e640. [PMID: 23706933 DOI: 10.1016/j.crohns.2013.05.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
336 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 30.0] [Reference Citation Analysis]
337 Shim TS. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy. Intest Res 2014;12:12-9. [PMID: 25349559 DOI: 10.5217/ir.2014.12.1.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
338 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
339 Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
340 Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y, Yamazaki H, Yoshida H, Nakamura T, Matsumoto S, Muramoto Y, Yamamoto S, Honzawa Y, Kuriyama K, Okamoto K, Hirano T, Okada H, Marui S, Sogabe Y, Morita T, Matsumori T, Mima A, Nishikawa Y, Ueda T, Matsumura K, Uza N, Chiba T, Seno H. Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology 2021;160:2383-2394.e21. [PMID: 33582126 DOI: 10.1053/j.gastro.2021.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
341 Román J, Planell N, Lozano JJ, Aceituno M, Esteller M, Pontes C, Balsa D, Merlos M, Panés J, Salas A. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis 2013;19:221-9. [PMID: 22605655 DOI: 10.1002/ibd.23020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
342 Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology 2020;158:2139-2149.e14. [PMID: 32092309 DOI: 10.1053/j.gastro.2020.02.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 35.0] [Reference Citation Analysis]
343 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 61.3] [Reference Citation Analysis]
344 Jiang X, Yang Y, Stier E. Bioequivalence for Drug Products Acting Locally Within Gastrointestinal Tract. In: Yu LX, Li BV, editors. FDA Bioequivalence Standards. New York: Springer; 2014. pp. 297-334. [DOI: 10.1007/978-1-4939-1252-0_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
345 Meyer C, Bowers A, Wayant C, Checketts J, Scott J, Musuvathy S, Vassar M. Scientific evidence underlying the American College of Gastroenterology's clinical practice guidelines. PLoS One 2018;13:e0204720. [PMID: 30281671 DOI: 10.1371/journal.pone.0204720] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
346 Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. Clin Gastroenterol Hepatol 2017;15:1218-1225.e7. [PMID: 27913244 DOI: 10.1016/j.cgh.2016.11.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
347 Rolny P, Vatn M. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. Scand J Gastroenterol 2013;48:131-5. [PMID: 23110487 DOI: 10.3109/00365521.2012.733954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
348 Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs Aging 2017;34:859-68. [PMID: 29170864 DOI: 10.1007/s40266-017-0498-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
349 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
350 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 302] [Article Influence: 180.5] [Reference Citation Analysis]
351 Lasch K, Liu S, Ursos L, Mody R, King-Concialdi K, DiBonaventura M, Leberman J, Dubinsky M. Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey. Adv Ther 2016;33:1715-27. [PMID: 27509887 DOI: 10.1007/s12325-016-0393-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
352 Bellera CL, Di Ianni ME, Talevi A. The application of molecular topology for ulcerative colitis drug discovery. Expert Opin Drug Discov 2018;13:89-101. [PMID: 29088918 DOI: 10.1080/17460441.2018.1396314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
353 Kerman DH, Deshpande AR. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. Postgrad Med. 2014;126:7-19. [PMID: 25141239 DOI: 10.3810/pgm.2014.07.2779] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
354 Elia J, Kane S. Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. Inflamm Bowel Dis. 2018;24:2543-2549. [PMID: 29850914 DOI: 10.1093/ibd/izy199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
355 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
356 Navaneethan U, Venkatesh PG, Shen B. Risks and benefits of ileal pouch–anal anastomosis for ulcerative colitis. Therapy 2011;8:83-99. [DOI: 10.2217/thy.10.87] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
357 Song G, Fiocchi C, Achkar JP. Acupuncture in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1129-39. [PMID: 30535303 DOI: 10.1093/ibd/izy371] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
358 Dong Y, Zhou Z, Ding H, Zhang S. Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid. Pharm Dev Technol 2014;19:960-7. [PMID: 24320757 DOI: 10.3109/10837450.2013.846372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
359 Bryant RV, Jairath V, Curry N, Travis SP. Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? J Crohns Colitis. 2014;8:166-171. [PMID: 24095288 DOI: 10.1016/j.crohns.2013.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
360 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
361 Hong SN. Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease. Clin Endosc 2017;50:437-45. [PMID: 29017293 DOI: 10.5946/ce.2017.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
362 Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol 2014; 20(44): 16389-16397 [PMID: 25469007 DOI: 10.3748/wjg.v20.i44.16389] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
363 Park SC, Jeen YM, Jeen YT. Approach to cytomegalovirus infections in patients with ulcerative colitis. Korean J Intern Med 2017;32:383-92. [PMID: 28490715 DOI: 10.3904/kjim.2017.087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
364 Schots L, Grine L, Soenen R, Lambert J. Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey. J Dermatolog Treat 2020;:1-9. [PMID: 33019835 DOI: 10.1080/09546634.2020.1832649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
366 van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci 2014;59:554-63. [PMID: 23949640 DOI: 10.1007/s10620-013-2820-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
367 Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. Aliment Pharmacol Ther 2016;44:482-94. [DOI: 10.1111/apt.13700] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
368 Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2017;23:570-577. [PMID: 28230558 DOI: 10.1097/mib.0000000000001049] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 17.7] [Reference Citation Analysis]
369 Regan BP, Bousvaros A. Pediatric Ulcerative Colitis: A Practical Guide to Management. Pediatr Drugs 2014;16:189-98. [DOI: 10.1007/s40272-014-0070-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
370 Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. Am J Gastroenterol 2018;113:1801-9. [PMID: 30353058 DOI: 10.1038/s41395-018-0354-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
371 Loftus EV Jr, Davis KL, Wang CC, Dastani H, Luo A. Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. Inflamm Bowel Dis 2014;20:1361-7. [PMID: 24918320 DOI: 10.1097/MIB.0000000000000089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
372 Rubio CA. Lysozyme expression in microscopic colitis. J Clin Pathol 2011;64:510-5. [PMID: 21460390 DOI: 10.1136/jcp.2010.086850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
373 Huguet JM, Suárez P, Ferrer-Barceló L, Ruiz L, Monzó A, Durá AB, Sempere J. Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations. World J Gastrointest Endosc 2017; 9(6): 255-262 [PMID: 28690768 DOI: 10.4253/wjge.v9.i6.255] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
374 Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. Pharmacoeconomics. 2017;36:419-434. [PMID: 29260508 DOI: 10.1007/s40273-017-0601-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
375 Bernick SJ, Kane S. Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence. Patient Relat Outcome Meas 2010;1:57-63. [PMID: 22915953 DOI: 10.2147/prom.s8382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
376 Na SY, Moon W. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. Korean J Gastroenterol 2018;71:61-8. [PMID: 29471602 DOI: 10.4166/kjg.2018.71.2.61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
377 Katz S, Surawicz C, Pardi DS. Management of the Elderly Patients with Inflammatory Bowel Disease: Practical Considerations. Inflammatory Bowel Diseases 2013;19:2257-72. [DOI: 10.1097/mib.0b013e31828c8536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
378 Ahn JY, Lee KH, Choi CH, Kim JW, Lee HW, Kim JW, Kim MK, Kwon GY, Han S, Kim SE. Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci. 2014;59:1001-1011. [PMID: 24282051 DOI: 10.1007/s10620-013-2930-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
379 Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507-515. [PMID: 25870198 DOI: 10.1093/ecco-jcc/jjv059] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
380 Weitzel KW, Smith DM, Elsey AR, Duong BQ, Burkley B, Clare-Salzler M, Gong Y, Higgins TA, Kong B, Langaee T, McDonough CW, Staley BJ, Vo TT, Wake DT, Cavallari LH, Johnson JA. Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clin Transl Sci 2018;11:175-81. [PMID: 29351371 DOI: 10.1111/cts.12533] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
381 Johnson SL, Palta M, Bartels CM, Thorpe CT, Weiss JM, Smith MA. Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. BMC Pharmacol Toxicol 2015;16:34. [PMID: 26643112 DOI: 10.1186/s40360-015-0034-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
382 Siddique I, Alazmi W, Al-ali J, Longenecker JC, Al-fadli A, Hasan F, Memon A. Demography and clinical course of ulcerative colitis in Arabs – a study based on the Montreal classification. Scandinavian Journal of Gastroenterology 2014;49:1432-40. [DOI: 10.3109/00365521.2014.966318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
383 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
384 Wiernicka A, Szymanska S, Cielecka-Kuszyk J, Dadalski M, Kierkus J. Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol 2015; 21(37): 10654-10661 [PMID: 26457025 DOI: 10.3748/wjg.v21.i37.10654] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
385 Zhao LN, Li JY, Yu T, Chen GC, Yuan YH, Chen QK. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014;9:e94208. [PMID: 24710620 DOI: 10.1371/journal.pone.0094208] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
386 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
387 Löwenberg M, de Boer NKh, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:53-9. [PMID: 24648749 DOI: 10.2147/CEG.S48741] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
388 Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996-1009. [PMID: 21385194 DOI: 10.1111/j.1365-2036.2011.04619.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
389 Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Curr Med Res Opin 2019;35:1751-9. [PMID: 31106607 DOI: 10.1080/03007995.2019.1620713] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
390 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
391 Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. J Clin Gastroenterol 2016;50:318-25. [PMID: 26368296 DOI: 10.1097/MCG.0000000000000414] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
392 Weizman AV, Nguyen GC. Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. World J Gastroenterol 2013; 19(38): 6375-6382 [PMID: 24151356 DOI: 10.3748/wjg.v19.i38.6375] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
393 Ihara S, Yamaji Y, Kinoshita H, Yamada A, Hirata Y, Hasegawa K, Sugawara Y, Kokudo N, Koike K. First case report of de novo ulcerative colitis developing after orthotopic liver transplantation successfully treated by granulocyte and monocyte apheresis. Transplant Proc 2014;46:2414-7. [PMID: 25015850 DOI: 10.1016/j.transproceed.2014.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
394 Lichtenstein GR, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. Inflamm Bowel Dis 2014;20:1399-406. [PMID: 24874460 DOI: 10.1097/MIB.0000000000000076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
395 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
396 Jiang XL, Cui HF, Gao J, Fan H. Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis. J Clin Gastroenterol 2015;49:582-8. [PMID: 25844841 DOI: 10.1097/MCG.0000000000000319] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 5.6] [Reference Citation Analysis]
397 Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol 2016; 22(3): 895-905 [PMID: 26811635 DOI: 10.3748/wjg.v22.i3.895] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 78] [Article Influence: 21.0] [Reference Citation Analysis]
398 Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res 2016;14:248-57. [PMID: 27433147 DOI: 10.5217/ir.2016.14.3.248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
399 Kawalec P, Stawowczyk E, Mossakowska M, Pilc A. Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland. Prz Gastroenterol 2017;12:60-5. [PMID: 28337239 DOI: 10.5114/pg.2017.66324] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
400 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol 2014; 20(37): 13234-13238 [PMID: 25309060 DOI: 10.3748/wjg.v20.i37.13234] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
401 Limdi JK, Farraye FA. An Update on Surveillance in Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:7. [PMID: 29516293 DOI: 10.1007/s11894-018-0612-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
402 Hao Y, Nagase K, Hori K, Wang S, Kogure Y, Fukunaga K, Kashiwamura S, Yamamoto S, Nakamura S, Li J, Miwa H, Noguchi K, Dai Y. Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair. Evid Based Complement Alternat Med 2014;2014:569587. [PMID: 25120575 DOI: 10.1155/2014/569587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
403 Olaisen M, Rydning A, Martinsen TC, Nordrum IS, Mjønes P, Fossmark R. Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. Scandinavian Journal of Gastroenterology 2014;49:845-52. [DOI: 10.3109/00365521.2014.929172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
404 Chandradas S, Khalili H, Ananthakrishnan A, Wayman C, Reidel W, Waalen J, Konijeti GG. Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis? Dig Dis Sci 2018;63:2445-50. [PMID: 29779082 DOI: 10.1007/s10620-018-5108-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
405 Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11:e0165435. [PMID: 27776175 DOI: 10.1371/journal.pone.0165435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 11.6] [Reference Citation Analysis]
406 Weng MT, Tung CC, Lee YS, Leong YL, Shieh MJ, Shun CT, Wang CY, Wong JM, Wei SC. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017;17:28. [PMID: 28193173 DOI: 10.1186/s12876-017-0586-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
407 Feinberg AE, Barnard M, Feinberg SM. Primary linitis plastica of the entire colon in a background of ulcerative colitis: a case report. World J Surg Oncol 2015;13:16. [PMID: 25649787 DOI: 10.1186/s12957-014-0425-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
408 Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J, Feagins LA, Khan N, Good CB, Vijan S, Higgins PD. Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort. PLoS One. 2016;11:e0158017. [PMID: 27336296 DOI: 10.1371/journal.pone.0158017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
409 Richter JM, Kushkuley S, Barrett JA, Oster G. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. Aliment Pharmacol Ther. 2012;36:248-256. [PMID: 22690748 DOI: 10.1111/j.1365-2036.2012.05175.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
410 Sehgal P, Colombel J, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther 2018;47:1597-609. [DOI: 10.1111/apt.14688] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
411 Eugène C. Ulcerative colitis practice guidelines in adults. Clin Res Hepatol Gastroenterol. 2012;36:107-109. [PMID: 22236738 DOI: 10.1016/j.clinre.2011.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
412 Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J Gastroenterol 2014; 20(29): 9872-9881 [PMID: 25110418 DOI: 10.3748/wjg.v20.i29.9872] [Cited by in CrossRef: 196] [Cited by in F6Publishing: 177] [Article Influence: 28.0] [Reference Citation Analysis]
413 Stawowczyk E, Kawalec P, Pilc A. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy 2016;36:472-81. [PMID: 27007213 DOI: 10.1002/phar.1742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
414 Li G, Zeng S, Liao W, Lv N. The effect of bifid triple viable on immune function of patients with ulcerative colitis. Gastroenterol Res Pract 2012;2012:404752. [PMID: 22927836 DOI: 10.1155/2012/404752] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
415 Zhao X, Zhou C, Ma J, Zhu Y, Sun M, Wang P, Zhang Y, Ma H, Zhang H. Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Sci Rep 2017;7:46693. [PMID: 28440311 DOI: 10.1038/srep46693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
416 Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
417 Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med. 2016;12:829-834. [PMID: 27446283 DOI: 10.3892/etm.2016.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
418 Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res 2017;9:641-52. [PMID: 29081667 DOI: 10.2147/CEOR.S135609] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
419 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 10.8] [Reference Citation Analysis]
420 Fiorino G, Gilardi D, Naccarato P, Sociale OR, Danese S. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. Dig Liver Dis 2014;46:330-4. [PMID: 24462118 DOI: 10.1016/j.dld.2013.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
421 Zhou F, Wang N, Yang L, Zhang L, Meng L, Xia Y. Saikosaponin A protects against dextran sulfate sodium-induced colitis in mice. International Immunopharmacology 2019;72:454-8. [DOI: 10.1016/j.intimp.2019.04.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
422 Sood A, Mahajan R, Singh A, Midha V, Mehta V, Narang V, Singh T, Singh Pannu A. Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. J Crohns Colitis. 2019;13:1311-1317. [PMID: 30873549 DOI: 10.1093/ecco-jcc/jjz060] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 48.0] [Reference Citation Analysis]
423 Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:630-642. [PMID: 21407186 DOI: 10.1038/ajg.2011.64] [Cited by in Crossref: 160] [Cited by in F6Publishing: 150] [Article Influence: 16.0] [Reference Citation Analysis]
424 Sriram A, Tangirala S, Atmakuri S, Hoque S, Modani S, Srivastava S, Mahajan S, Maji I, Kumar R, Khatri D, Madan J, Singh PK. Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech 2021;22:264. [PMID: 34734325 DOI: 10.1208/s12249-021-02133-4] [Reference Citation Analysis]
425 Pai RK, Hartman DJ, Leighton JA, Pasha SF, Ramos Rivers C, Regueiro M, Binion DG, Pai RK. Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. J Crohns Colitis 2021:jjab042. [PMID: 33687061 DOI: 10.1093/ecco-jcc/jjab042] [Reference Citation Analysis]
426 Ham NS, Myung SJ. Endoscopic molecular imaging in inflammatory bowel disease. Intest Res 2021;19:33-44. [PMID: 32299156 DOI: 10.5217/ir.2019.09175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
427 Beg S, Wilson A, Ragunath K. The use of optical imaging techniques in the gastrointestinal tract. Frontline Gastroenterol 2016;7:207-15. [PMID: 27429735 DOI: 10.1136/flgastro-2015-100563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
428 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
429 Lee KE, Jung S, Yoon H, Park SH, Moon CM, Kim ES, Kim S, Yang S. Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2017;52:833-9. [DOI: 10.1080/00365521.2017.1310288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
430 Pöllinger B, Schmidt W, Seiffert A, Imhoff H, Emmert M. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ 2019;20:195-203. [PMID: 29362899 DOI: 10.1007/s10198-017-0953-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
431 Feuerstein JD, Jiang ZG, Belkin E, Lewandowski JJ, Martinez-vazquez M, Singla A, Cataldo T, Poylin V, Cheifetz AS. Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days: . Inflammatory Bowel Diseases 2015;21:2130-6. [DOI: 10.1097/mib.0000000000000473] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
432 Wei Y, Gong J, Zhu W, Tian H, Ding C, Gu L, Li N, Li J. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiol 2016;16:255. [PMID: 27809778 DOI: 10.1186/s12866-016-0869-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
433 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
434 Trindade AJ, Morisky DE, Ehrlich AC, Tinsley A, Ullman TA. Current practice and perception of screening for medication adherence in inflammatory bowel disease. J Clin Gastroenterol. 2011;45:878-882. [PMID: 21555953 DOI: 10.1097/mcg.0b013e3182192207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
435 Razik R, Bernstein CN, Sam J, Thanabalan R, Nguyen GC. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol 2012;26:795-8. [PMID: 23166902 DOI: 10.1155/2012/175249] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
436 Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis. J Gastroenterol 2020;55:667-78. [PMID: 32367294 DOI: 10.1007/s00535-020-01692-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
437 Har-Noy O, Katz L, Avni T, Battat R, Bessissow T, Yung DE, Engel T, Koulaouzidis A, Eliakim R, Ben-Horin S, Kopylov U. Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. Dig Dis Sci. 2017;62:2982-2990. [PMID: 28965228 DOI: 10.1007/s10620-017-4772-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
438 Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol 2017;33:8-13. [PMID: 28134687 DOI: 10.1097/MOG.0000000000000326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
439 Zhao JJ, Wang D, Yao H, Sun DW, Li HY. CTLA-4 and MDR1 polymorphisms increase the risk for ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(34): 10025-10040 [PMID: 26379408 DOI: 10.3748/wjg.v21.i34.10025] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
440 Abhyankar A, Moss AC. Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015;21:1976-81. [PMID: 25844962 DOI: 10.1097/MIB.0000000000000386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
441 Ramadass SK, Perumal S, Jabaris SL, Madhan B. Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis. Eur J Pharm Sci. 2013;48:104-110. [PMID: 23137838 DOI: 10.1016/j.ejps.2012.10.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
442 Park JR, Pfeil SA. Primary Care of the Patient with Inflammatory Bowel Disease. Med Clin North Am 2015;99:969-87. [PMID: 26320042 DOI: 10.1016/j.mcna.2015.05.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
443 Ley D, Martin B, Caldera F. Use of an iPhone Application to Increase Adherence in Patients With Ulcerative Colitis in Remission: A Randomized Controlled Trial. Inflamm Bowel Dis 2020;26:e33-4. [PMID: 32086525 DOI: 10.1093/ibd/izaa024] [Reference Citation Analysis]
444 Brady JE, Stott-miller M, Mu G, Perera S. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. Clinical Therapeutics 2018;40:1509-1521.e5. [DOI: 10.1016/j.clinthera.2018.07.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
445 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
446 Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 2016;44:157-69. [PMID: 27218676 DOI: 10.1111/apt.13653] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
447 Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res 2019;17:375-86. [PMID: 30739435 DOI: 10.5217/ir.2018.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
448 Pandey M, Choudhury H, D/O Segar Singh SK, Chetty Annan N, Bhattamisra SK, Gorain B, Mohd Amin MCI. Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. Molecules 2021;26:2704. [PMID: 34062995 DOI: 10.3390/molecules26092704] [Reference Citation Analysis]
449 Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
450 Olech E. Biosimilars: Rationale and current regulatory landscape. Seminars in Arthritis and Rheumatism 2016;45:S1-S10. [DOI: 10.1016/j.semarthrit.2016.01.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
451 Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19:2155-2165. [PMID: 23899544 DOI: 10.1097/mib.0b013e31829ea325] [Cited by in Crossref: 166] [Cited by in F6Publishing: 104] [Article Influence: 23.7] [Reference Citation Analysis]
452 Lee HS, Yang SK, Soh JS, Lee S, Bae JH, Lee HJ, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH. Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 Cohort. Inflamm Bowel Dis 2015;21:1825-31. [PMID: 25985248 DOI: 10.1097/MIB.0000000000000447] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
453 Johnson DH, Khanna S, Smyrk TC, Loftus EV, Anderson KS, Mahoney DW, Ahlquist DA, Kisiel JB. Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn’s colitis. Aliment Pharmacol Ther. 2014;39:1408-1417. [PMID: 24779703 DOI: 10.1111/apt.12774] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
454 Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics 2013;14:835-43. [PMID: 23651030 DOI: 10.2217/pgs.13.52] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
455 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
456 Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17:1549-1559. [PMID: 27157244 DOI: 10.1080/14656566.2016.1183648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
457 Yee J, Kim SM, Han JM, Lee N, Yoon HY, Gwak HS. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep 2020;10:3658. [PMID: 32107440 DOI: 10.1038/s41598-020-60467-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
458 Tasende MM, Delgado S, Jimenez M, Del Gobbo GD, Fernández-Hevia M, DeLacy B, Balust J, Lacy AM. Minimal invasive surgery: NOSE and NOTES in ulcerative colitis. Surg Endosc. 2015;29:3313-3318. [PMID: 25669637 DOI: 10.1007/s00464-015-4087-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
459 Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-157. e2. [PMID: 23528626 DOI: 10.1053/j.gastro.2013.03.025] [Cited by in Crossref: 140] [Cited by in F6Publishing: 129] [Article Influence: 17.5] [Reference Citation Analysis]
460 Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis. Clinical Gastroenterology and Hepatology 2012;10:513-9. [DOI: 10.1016/j.cgh.2011.10.043] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
461 Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. Eur J Clin Microbiol Infect Dis. 2015;34:13-18. [PMID: 25097085 DOI: 10.1007/s10096-014-2212-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
462 Zhai J, Mantaj J, Vllasaliu D. Ascorbyl Palmitate Hydrogel for Local, Intestinal Delivery of Macromolecules. Pharmaceutics 2018;10:E188. [PMID: 30326565 DOI: 10.3390/pharmaceutics10040188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
463 Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1793-1800.e1. [PMID: 24907505 DOI: 10.1016/j.cgh.2014.05.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
464 Ha CY. Risks of Infection among the Older Inflammatory Bowel Disease Patients. Curr Treat Options Gastro 2014;12:283-91. [DOI: 10.1007/s11938-014-0023-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
465 Feuerstein JD, Rakowsky S, Sattler L, Yadav A, Foromera J, Grossberg L, Cheifetz AS. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019;pii:S0016-5107(19)31602-5. [PMID: 31009609 DOI: 10.1016/j.gie.2019.04.219] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
466 Love BL, Miller AD. Extended-release mesalamine granules for ulcerative colitis. Ann Pharmacother 2012;46:1529-36. [PMID: 23115226 DOI: 10.1345/aph.1R171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
467 Zhang Q, Deng Y, Wang J, Haung F, Zhou Y, Jia M, Yi H. Efficacy and safety of Shenling Atractylodes Powder in the treatment of ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25355. [PMID: 33832115 DOI: 10.1097/MD.0000000000025355] [Reference Citation Analysis]
468 Waljee AK, Stidham RW, Higgins PD, Vijan S, Saini SD. Point-counterpoint: Are we overtreating patients with mild ulcerative colitis? J Crohns Colitis 2014;8:80-4. [PMID: 23938211 DOI: 10.1016/j.crohns.2013.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
469 Lee NS, Pola S, Groessl EJ, Rivera-Nieves J, Ho SB. Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci 2016;61:1003-12. [PMID: 26860508 DOI: 10.1007/s10620-016-4046-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
470 Picco MF, Pasha S, Leighton JA, Bruining D, Loftus EV Jr, Thomas CS, Crook JE, Krishna M, Wallace M. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis. 2013;19:1913-1920. [PMID: 23811635 DOI: 10.1097/mib.0b013e3182902aba] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 0.4] [Reference Citation Analysis]
471 Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut. 2013;62:1642-1652. [PMID: 24104885 DOI: 10.1136/gutjnl-2012-303959] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
472 Koerdt S, Jehle EC, Kreis ME, Kasparek MS. Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Int J Colorectal Dis 2014;29:545-54. [DOI: 10.1007/s00384-013-1814-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
473 Cui DJ, Yang XL, Okuda S, Ling YW, Zhang ZX, Liu Q, Yuan WQ, Yan F. Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction. J Int Med Res 2020;48:300060520951023. [PMID: 33322986 DOI: 10.1177/0300060520951023] [Reference Citation Analysis]
474 Menta PLR, Andrade MER, Leocádio PCL, Fraga JR, Dias MTS, Cara DC, Cardoso VN, Borges LF, Capettini LSA, Aguilar EC, Alvarez-Leite JI. Wheat gluten intake increases the severity of experimental colitis and bacterial translocation by weakening of the proteins of the junctional complex. Br J Nutr 2019;121:361-73. [PMID: 30554574 DOI: 10.1017/S0007114518003422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
475 Lin YF, Sung CM, Ke HM, Kuo CJ, Liu WA, Tsai WS, Lin CY, Cheng HT, Lu MJ, Tsai IJ, Hsieh SY. The rectal mucosal but not fecal microbiota detects subclinical ulcerative colitis. Gut Microbes 2021;13:1-10. [PMID: 33525983 DOI: 10.1080/19490976.2020.1832856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Lemmens G, Van Camp A, Kourula S, Vanuytsel T, Augustijns P. Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics 2021;13:161. [PMID: 33530468 DOI: 10.3390/pharmaceutics13020161] [Reference Citation Analysis]
477 Shrestha MP, Taleban S. Management of Ulcerative Colitis in the Elderly. Drugs Aging 2019;36:13-27. [DOI: 10.1007/s40266-018-0611-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
478 Shah SC, Itzkowitz SH. Reappraising Risk Factors for Inflammatory Bowel Disease-associated Neoplasia: Implications for Colonoscopic Surveillance in IBD. J Crohns Colitis 2020;14:1172-7. [PMID: 32150256 DOI: 10.1093/ecco-jcc/jjaa040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
479 Levesque BG, Sandborn WJ. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet 2012;380:1887-8. [PMID: 23063315 DOI: 10.1016/S0140-6736(12)61259-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
480 Shinozaki M, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi KI, Iwao Y, Suzuki Y, Watanabe M, Itabashi M. Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. Dig Endosc. 2017;29:584-593. [PMID: 28066941 DOI: 10.1111/den.12803] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
481 Anzai H, Hata K, Kishikawa J, Ishii H, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Nozawa H, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Watanabe T. Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. Colorectal Dis 2016;18:O97-O102. [DOI: 10.1111/codi.13237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
482 Han Z, Wang H, Guo D, Zhang J. Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. Aging (Albany NY) 2021;13:5087-103. [PMID: 33535180 DOI: 10.18632/aging.202427] [Reference Citation Analysis]
483 Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:953-962. [PMID: 23550660 DOI: 10.1111/apt.12294] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 11.5] [Reference Citation Analysis]
484 Dorreen A, Heisler C, Jones J. Treatment of Inflammatory Bowel Disease in the Older Patient. Inflammatory Bowel Diseases 2018;24:1155-66. [DOI: 10.1093/ibd/izy023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Mannon PJ. Immunological Diseases of the Gastrointestinal Tract. Clinical Immunology. Elsevier; 2019. pp. 1005-1019.e1. [DOI: 10.1016/b978-0-7020-6896-6.00075-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
486 Kutsuna R, Miyoshi-Akiyama T, Tomida J, Kawamura Y. Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678T, Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis. Microbiol Resour Announc 2021;10:e0078021. [PMID: 34528815 DOI: 10.1128/MRA.00780-21] [Reference Citation Analysis]
487 Desai J, Elnaggar M, Hanfy AA, Doshi R. Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions. Clin Exp Gastroenterol 2020;13:203-10. [PMID: 32547151 DOI: 10.2147/CEG.S200760] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
488 Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882-893. [PMID: 28375885 DOI: 10.1097/mib.0000000000001099] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 10.7] [Reference Citation Analysis]
489 Leung K, Rhee G, Parlow S, Bollu A, Sabri E, McCurdy JD, Murthy SK. Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. J Can Assoc Gastroenterol 2020;3:169-76. [PMID: 32671326 DOI: 10.1093/jcag/gwz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
490 Vigsnaes LK, van den Abbeele P, Sulek K, Frandsen HL, Steenholdt C, Brynskov J, Vermeiren J, van de Wiele T, Licht TR. Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. Sci Rep. 2013;3:1110. [PMID: 23346367 DOI: 10.1038/srep01110] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
491 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 151] [Article Influence: 28.7] [Reference Citation Analysis]
492 Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, Cole AT, Cooper SC, Creed T, Cummings F, de Boer NK, D'Inca R, D'Souza R, Daneshmend TK, Delaney M, Dhar A, Direkze N, Dunckley P, Gaya DR, Gearry R, Gore S, Halfvarson J, Hart A, Hawkey CJ, Hoentjen F, Iqbal T, Irving P, Lal S, Lawrance I, Lees CW, Lockett M, Mann S, Mansfield J, Mowat C, Mulgrew CJ, Muller F, Murray C, Oram R, Orchard T, Parkes M, Phillips R, Pollok R, Radford-Smith G, Sebastian S, Sen S, Shirazi T, Silverberg M, Solomon L, Sturniolo GC, Thomas M, Tremelling M, Tsianos EV, Watts D, Weaver S, Weersma RK, Wesley E, Holden A, Ahmad T. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis 2016;10:149-58. [PMID: 26619893 DOI: 10.1093/ecco-jcc/jjv219] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
493 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
494 Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17(30): 3467-3478 [PMID: 21941413 DOI: 10.3748/wjg.v17.i30.3467] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
495 Galatola M, Miele E, Strisciuglio C, Paparo L, Rega D, Delrio P, Duraturo F, Martinelli M, Rossi GB, Staiano A, Izzo P, Rosa MD. Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J Gastroenterol 2013; 19(46): 8659-8670 [PMID: 24379584 DOI: 10.3748/wjg.v19.i46.8659] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
496 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
497 Xu M, Sun M, Qiao H, Ping Q, Elamin ES. Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid. International Journal of Pharmaceutics 2014;468:165-71. [DOI: 10.1016/j.ijpharm.2014.04.040] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
498 Levine A, Yerushalmi B, Kori M, Broide E, Mozer-glassberg Y, Shaoul R, Kolho K, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, Shabat CS, Focht G, Shachmon E, Boaz M, On A, Turner D. Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. Journal of Crohn's and Colitis 2017;11:970-4. [DOI: 10.1093/ecco-jcc/jjx042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
499 Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71:1599-1613. [PMID: 31436036 DOI: 10.1002/art.41042] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 62.0] [Reference Citation Analysis]
500 Leong RW, Ooi M, Corte C, Yau Y, Kermeen M, Katelaris PH, McDonald C, Ngu M. Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152:1337-1344.e3. [PMID: 28126349 DOI: 10.1053/j.gastro.2017.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
501 Hata K, Kishikawa J, Anzai H, Shinagawa T, Kazama S, Ishii H, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J. Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. Dig Endosc. 2016;28:260-265. [PMID: 26096182 DOI: 10.1111/den.12505] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
502 Abraham NS, Richardson P, Castillo D, Kane SV. Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2013;11:1281-7. [DOI: 10.1016/j.cgh.2013.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
503 Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflamm Bowel Dis 2021;27:1270-6. [PMID: 33165569 DOI: 10.1093/ibd/izaa293] [Reference Citation Analysis]
504 Hijikata Y, Matsubara Y, Ota Y, Lim LA, Tani K, Hirata Y, Yotsuyanagi H. Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. Intern Med 2020;59:1105-9. [PMID: 32009094 DOI: 10.2169/internalmedicine.3901-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
505 Dai YC, Zhang YL, Wang LJ, Guo Q, Yang K, Ye RH, Tang ZP. Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients. Chin J Integr Med. 2016;22:811-816. [PMID: 26501692 DOI: 10.1007/s11655-015-2118-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
506 Gallinger ZR, Rumman A, Murthy SK, Nguyen GC. Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. Endosc Int Open 2017;5:E974-9. [PMID: 28983504 DOI: 10.1055/s-0043-117944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
507 de Bock E, Filipe MD, Meij V, Oldenburg B, van Schaik FDM, Bastian OW, Fidder HF, Vriens MR, Richir MC. Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. BMJ Open Gastroenterol 2021;8:e000670. [PMID: 34215570 DOI: 10.1136/bmjgast-2021-000670] [Reference Citation Analysis]
508 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 17.7] [Reference Citation Analysis]
509 Reich JS, Farraye FA, Wasan SK. Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New? Dig Dis Sci 2016;61:2205-16. [DOI: 10.1007/s10620-016-4146-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
510 Tontini GE, Vecchi M, Neurath MF, Neumann H. Advanced endoscopic imaging techniques in Crohn’s disease. J Crohns Colitis. 2014;8:261-269. [PMID: 24080247 DOI: 10.1016/j.crohns.2013.09.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
511 Nguyen GC, Bollegala N, Chong CA. Factors associated with readmissions and outcomes of patients hospitalized for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1897-1904.e1. [PMID: 24681074 DOI: 10.1016/j.cgh.2014.02.042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
512 Sorita A, Thongprayoon C, Ahmed A, Bates RE, Ratelle JT, Rieck KM, Devalapalli AP, Issa M, Shah RM, Lalama MA, Wang Z, Murad MH, Kashiwagi DT. Frequency and Appropriateness of Fasting Orders in the Hospital. Mayo Clin Proc 2015;90:1225-32. [PMID: 26355400 DOI: 10.1016/j.mayocp.2015.07.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
513 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
514 Chiba M, Nakane K, Tsuji T, Tsuda S, Ishii H, Ohno H, Watanabe K, Obara Y, Komatsu M, Sugawara T. Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. Perm J 2019;23. [PMID: 31050638 DOI: 10.7812/TPP/18-220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
515 van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, Eshuis EJ, Ponsioen CY, Siersema PD, van Oijen MG, Oldenburg B;  Dutch Initiative on Crohn and Colitis (ICC). Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014;46:881-886. [PMID: 25081843 DOI: 10.1016/j.dld.2014.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
516 Chang M, Chang L, Chang HM, Chang F. Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease. Clinical Colorectal Cancer 2018;17:e29-37. [DOI: 10.1016/j.clcc.2017.06.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
517 Smith MA, Mohammad RA. Vedolizumab: An α 4 β 7 Integrin Inhibitor for Inflammatory Bowel Diseases. Ann Pharmacother 2014;48:1629-35. [DOI: 10.1177/1060028014549799] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
518 Sheriff MZ, Mansoor E, Luther J, Ananthakrishnan AN, Abou Saleh M, Ho E, Briggs FBS, Dave M. Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study. Inflamm Bowel Dis 2020;26:291-300. [PMID: 31314891 DOI: 10.1093/ibd/izz147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
519 Vaughn BP, Doherty GA, Gautam S, Moss AC, Cheifetz AS. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18:1057-1063. [PMID: 21953829 DOI: 10.1002/ibd.21824] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
520 Naymagon S, Marion JF. Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement. Gastrointest Endosc Clin N Am 2013;23:679-94. [PMID: 23735110 DOI: 10.1016/j.giec.2013.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
521 Banerjee A, Scarpa M, Pathak S, Burra P, Sturniolo GC, Russo FP, Murugesan R, D'Incá R. Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. Endocr Metab Immune Disord Drug Targets 2019;19:959-74. [PMID: 30864530 DOI: 10.2174/1871530319666190313112110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
522 Raskin JB, Kamm MA, Jamal MM, Márquez J, Melzer E, Schoen RE, Szalóki T, Barrett K, Streck P. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology. 2014;147:793-802. [PMID: 25038431 DOI: 10.1053/j.gastro.2014.07.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 9.1] [Reference Citation Analysis]
523 Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714-1721. [PMID: 25069030 DOI: 10.1097/mib.0000000000000138] [Cited by in Crossref: 61] [Cited by in F6Publishing: 26] [Article Influence: 10.2] [Reference Citation Analysis]
524 Gregory MH, McKinnon A, Stwalley D, Hippensteel KJ, Loftus EV Jr, Ciorba MA, Olsen MA, Deepak P. Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. J Crohns Colitis 2019;13:182-8. [PMID: 30256926 DOI: 10.1093/ecco-jcc/jjy148] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
525 Wang S, Tao P, Zhao L, Zhang W, Hu H, Lin J. Panax notoginseng Promotes Repair of Colonic Microvascular Injury in Sprague-Dawley Rats with Experimental Colitis. Evid Based Complement Alternat Med 2018;2018:4386571. [PMID: 29785192 DOI: 10.1155/2018/4386571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
526 Kwak MS, Cha JM, Ahn JH, Chae MK, Jeong S, Lee HH. Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study. Medicine (Baltimore) 2020;99:e18925. [PMID: 32150045 DOI: 10.1097/MD.0000000000018925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Strong SA. Management of acute colitis and toxic megacolon. Clin Colon Rectal Surg 2010;23:274-84. [PMID: 22131898 DOI: 10.1055/s-0030-1268254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
528 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
529 Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002-7; quiz e78. [PMID: 22343692 DOI: 10.1016/j.cgh.2012.02.004] [Cited by in Crossref: 153] [Cited by in F6Publishing: 138] [Article Influence: 17.0] [Reference Citation Analysis]
530 Sheng Y, Wu T, Dai Y, Ji K, Zhong Y, Xue Y. The effect of 6-gingerol on inflammatory response and Th17/Treg balance in DSS-induced ulcerative colitis mice. Ann Transl Med 2020;8:442. [PMID: 32395486 DOI: 10.21037/atm.2020.03.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
531 Adiga A, Goldfarb DS. The Association of Mesalamine With Kidney Disease. Adv Chronic Kidney Dis 2020;27:72-6. [PMID: 32147005 DOI: 10.1053/j.ackd.2019.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
532 Hagelund LM, Elkjær Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin 2020;36:771-9. [PMID: 31944145 DOI: 10.1080/03007995.2020.1716704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Khalid S, Abbass A, Khetpal N, Shen B, Navaneethan U. Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos. Int J Colorectal Dis 2019;34:569-80. [PMID: 30854573 DOI: 10.1007/s00384-019-03269-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
534 Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2019;156:946-957.e18. [PMID: 30472236 DOI: 10.1053/j.gastro.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
535 Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103. [PMID: 24641622 DOI: 10.1111/apt.12712] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
536 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
537 Rottoli M, Tanzanu M, Di Candido F, Colombo F, Frontali A, Chandrasinghe PC, Pellino G, Frasson M, Warusavitarne J, Panis Y, Sampietro GM, Spinelli A, Poggioli G. Risk factors for locally advanced cancer associated with ulcerative colitis: Results of a retrospective multicentric study in the era of biologics. Digestive and Liver Disease 2020;52:33-7. [DOI: 10.1016/j.dld.2019.08.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
538 Chiu Y, Chen C, Ko C, Liao S, Yeh H, Chang C. Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. Adv in Digestive Med 2021;8:40-6. [DOI: 10.1002/aid2.13188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
539 Trent RJ, Cheong PL, Chua EW, Kennedy MA. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. Pathology 2013;45:357-70. [PMID: 23594690 DOI: 10.1097/PAT.0b013e328360b66e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
540 Kruis W, Leifeld L, Morgenstern J, Pfützer R, Reimers B, Ceplis-Kastner S; CARE study group. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study. J Crohns Colitis 2013;7:e125-32. [PMID: 22951030 DOI: 10.1016/j.crohns.2012.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
541 Ford AC, Khan KJ, Achkar J, Moayyedi P. Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2012;107:167-76. [DOI: 10.1038/ajg.2011.410] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
542 Kato J, Kuriyama M, Hiraoka S, Yamamoto K. Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients? J Gastroenterol Hepatol 2011;26:683-7. [PMID: 21054518 DOI: 10.1111/j.1440-1746.2010.06562.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
543 Hosoe N, Matsuoka K, Naganuma M, Ida Y, Ishibashi Y, Kimura K, Yoneno K, Usui S, Kashiwagi K, Hisamatsu T, Inoue N, Kanai T, Imaeda H, Ogata H, Hibi T. Applicability of second-generation colon capsule endoscope to ulcerative colitis: A clinical feasibility study: Applicability of colon capsule endoscope. J Gastroenterol Hepatol 2013;28:1174-9. [DOI: 10.1111/jgh.12203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
544 Kato S, Ishibashi A, Kani K, Yakabi K. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Digestion 2018;97:59-63. [DOI: 10.1159/000484224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
545 Kiran RP, Ahmed Ali U, Nisar PJ, Khoury W, Gu J, Shen B, Remzi FH, Hammel JP, Lavery IC, Fazio VW. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg. 2014;259:302-309. [PMID: 23579580 DOI: 10.1097/sla.0b013e31828e7417] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
546 Hashash JG, Hartman DJ. Inflammatory cells implicated in neoplasia development in idiopathic inflammatory bowel disease. Cell Immunol 2019;343:103720. [PMID: 29221690 DOI: 10.1016/j.cellimm.2017.11.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
547 Korelitz BI. Expert opinion: Experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. World J Gastroenterol 2013; 19(20): 2979-2984 [PMID: 23716977 DOI: 10.3748/wjg.v19.i20.2979] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
548 Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh 2015;87:34-8. [PMID: 25864346 DOI: 10.17116/terarkh201587234-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
549 Baek SJ, Lee KY, Song KH, Yu CS. Current Status and Trends in Inflammatory Bowel Disease Surgery in Korea: Analysis of Data in a Nationwide Registry. Ann Coloproctol 2018;34:299-305. [PMID: 30630303 DOI: 10.3393/ac.2018.07.21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
550 Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev 2017;2017:4535194. [PMID: 28744337 DOI: 10.1155/2017/4535194] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 36.0] [Reference Citation Analysis]
551 Nam K, Park SH, Oh JH, Lee HS, Noh S, Park JC, Kim JY, Oh EH, Kim J, Ham NS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. BMC Gastroenterol 2021;21:13. [PMID: 33407193 DOI: 10.1186/s12876-020-01597-1] [Reference Citation Analysis]
552 Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, Ciorba MA, Sayuk GS. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423-9. [PMID: 24406434 DOI: 10.1097/MCG.0000000000000049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
553 Khazraei H, Bananzadeh A, Hosseini SV. Early Outcome of Patient with Ulcerative Colitis who Received High Dose of Steroid and Underwent Two Staged Total Proctocolectomy. Adv Biomed Res 2018;7:11. [PMID: 29456982 DOI: 10.4103/abr.abr_175_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
554 Maggiori L, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol. 2013;10:297-306. [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
555 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
556 Seo SH, Unno T, Park SE, Kim EJ, Lee YM, Na CS, Son HS. Korean Traditional Medicine (Jakyakgamcho-tang) Ameliorates Colitis by Regulating Gut Microbiota. Metabolites 2019;9:E226. [PMID: 31615012 DOI: 10.3390/metabo9100226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
557 Lee J, Clarke K. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. Int J Colorectal Dis 2015;30:1595-602. [DOI: 10.1007/s00384-015-2344-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
558 Megna B, Saha S, Wald A, Agni R, Matkowskyj KA, Caldera F. Symptomatic Microscopic Colitis Atop Quiescent Inflammatory Bowel Disease: A Case Series. ACG Case Rep J 2017;4:e124. [PMID: 29299484 DOI: 10.14309/crj.2017.124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
559 Feuerstein JD, Curran T, Alosilla M, Cataldo T, Falchuk KR, Poylin V. Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common.Dig Dis Sci. 2018;63:713-722. [PMID: 29353444 DOI: 10.1007/s10620-018-4922-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
560 Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3. [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 15.4] [Reference Citation Analysis]
561 Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One 2017;12:e0175099. [PMID: 28426675 DOI: 10.1371/journal.pone.0175099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
562 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 36] [Article Influence: 30.0] [Reference Citation Analysis]
563 Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. J Can Assoc Gastroenterol. 2018;1:129-134. [PMID: 31294354 DOI: 10.1093/jcag/gwy019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
564 Dulai PS, Sandborn WJ, Gupta S. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016;9:887-894. [PMID: 27679553 DOI: 10.1158/1940-6207.capr-16-0124] [Cited by in Crossref: 74] [Cited by in F6Publishing: 32] [Article Influence: 14.8] [Reference Citation Analysis]
565 Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427-37. [PMID: 24908178 DOI: 10.1016/j.crohns.2014.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
566 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 10.6] [Reference Citation Analysis]
567 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
568 Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835-848.e6. [PMID: 24462530 DOI: 10.1053/j.gastro.2014.01.042] [Cited by in Crossref: 152] [Cited by in F6Publishing: 127] [Article Influence: 21.7] [Reference Citation Analysis]
569 Krugliak Cleveland N, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Rubin DT. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis 2016;22:631-7. [PMID: 26658214 DOI: 10.1097/MIB.0000000000000634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
570 Huang V, Mishra R, Thanabalan R, Nguyen GC. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J Crohns Colitis. 2013;7:e318-e324. [PMID: 23265763 DOI: 10.1016/j.crohns.2012.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
571 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
572 Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci 2015;60:3408-17. [PMID: 26386854 DOI: 10.1007/s10620-015-3868-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
573 Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264-273. [PMID: 23734840 DOI: 10.1111/apt.12362] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
574 Guo Z, Bai Y, Zhang Z, Mei H, Li J, Pu Y, Zhao N, Gao W, Wu F, He B, Xie J. Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment. J Mater Chem B 2021;9:3874-84. [PMID: 33928321 DOI: 10.1039/d1tb00499a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
575 Muñiz Pedrogo DA, Chen J, Hillmann B, Jeraldo P, Al-Ghalith G, Taneja V, Davis JM, Knights D, Nelson H, Faubion WA, Raffals L, Kashyap PC. An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. Inflamm Bowel Dis 2019;25:902-13. [PMID: 30321331 DOI: 10.1093/ibd/izy318] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
576 Yang QY, Ma LL, Zhang C, Lin JZ, Han L, He YN, Xie CG. Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota. Front Pharmacol 2021;12:674416. [PMID: 34366843 DOI: 10.3389/fphar.2021.674416] [Reference Citation Analysis]
577 Verdon C, Aruljothy A, Lakatos PL, Bessissow T. Endoscopic surveillance strategies for dysplasia in ulcerative colitis. Frontline Gastroenterol 2020;11:124-32. [PMID: 32133111 DOI: 10.1136/flgastro-2018-101056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
578 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
579 Kondo S, Araki T, Toiyama Y, Tanaka K, Kawamura M, Okugawa Y, Okita Y, Saigusa S, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer. Oncol Lett. 2018;16:3658-3664. [PMID: 30127975 DOI: 10.3892/ol.2018.9120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
580 Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015;148:740-750.e2. [PMID: 25644096 DOI: 10.1053/j.gastro.2015.01.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 10.7] [Reference Citation Analysis]
581 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
582 Davis SC, Robinson BL, Vess J, Lebel JS. Primary care management of ulcerative colitis. The Nurse Practitioner 2018;43:11-9. [DOI: 10.1097/01.npr.0000527565.05934.14] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
583 Umar S, Clarke K, Bilimoria F, Bilal M, Singh S, Silverman J. Diagnostic yield from colon biopsies in patients with inflammatory bowel disease and suspected cytomegalovirus infection: is it worth it? Ann Gastroenterol 2017;30:429-32. [PMID: 28655979 DOI: 10.20524/aog.2017.0153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
584 Eaton JE, Smyrk TC, Imam M, Pardi DS, Loftus EV Jr, Owens VL, Talwalkar JA. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. Aliment Pharmacol Ther 2013;38:977-87. [PMID: 24033551 DOI: 10.1111/apt.12469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
585 Toyokawa Y, Takagi T, Uchiyama K, Mizushima K, Inoue K, Ushiroda C, Kashiwagi S, Nakano T, Hotta Y, Tanaka M, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Handa O, Konishi H, Naito Y, Itoh Y. Ginsenoside Rb1 promotes intestinal epithelial wound healing through extracellular signal‐regulated kinase and Rho signaling. Journal of Gastroenterology and Hepatology 2019;34:1193-200. [DOI: 10.1111/jgh.14532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
586 Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341-348. [PMID: 24094598 DOI: 10.1016/j.crohns.2013.09.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
587 Carvalho ATP, Esberard BC, Fróes RSB, Rapozo DCM, Grinman AB, Simão TA, Santos JCVC, Carneiro AJV, Ribeiro-Pinto LF, Souza HSP. Thiopurine-methyltransferase variants in inflammatory bowel disease: Prevalence and toxicity in Brazilian patients. World J Gastroenterol 2014; 20(12): 3327-3334 [PMID: 24696613 DOI: 10.3748/wjg.v20.i12.3327] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
588 Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) 2017;96:e6788. [PMID: 28562531 DOI: 10.1097/MD.0000000000006788] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
589 Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, Kiran RP. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohns Colitis. 2013;7:e684-e691. [PMID: 23916526 DOI: 10.1016/j.crohns.2013.06.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
590 Machin M, Younan HC, Slesser AAP, Mohsen Y. Systematic review on the management of ileoanal pouch-vaginal fistulas after restorative proctocolectomy in the treatment of ulcerative colitis. Colorectal Dis 2021;23:34-51. [PMID: 32810915 DOI: 10.1111/codi.15318] [Reference Citation Analysis]
591 Gondal B, Haider H, Komaki Y, Komaki F, Micic D, Rubin DT, Sakuraba A. Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: A systematic review and network meta-analysis. World J Gastrointest Endosc 2020; 12(5): 159-171 [PMID: 32477450 DOI: 10.4253/wjge.v12.i5.159] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1435-41. [PMID: 26978725 DOI: 10.1097/MIB.0000000000000747] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
593 Sands K, Jansen R, Zaslau S, Greenwald D. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 2015;41:821-34. [DOI: 10.1111/apt.13142] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
594 Panés J, Alfaro I. New treatment strategies for ulcerative colitis. Expert Rev Clin Immunol 2017;13:963-73. [PMID: 28617055 DOI: 10.1080/1744666X.2017.1343668] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
595 管丽芳, 胡博文, 孙琳, 廉方, 刘同亭. 妊娠期炎症性肠病的治疗策略与动态管理. 世界华人消化杂志 2016; 24(28): 3978-3984 [DOI: 10.11569/wcjd.v24.i28.3978] [Reference Citation Analysis]
596 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
597 Danese S, Bonovas S, Peyrin-Biroulet L. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis 2017;11:767-8. [PMID: 28333203 DOI: 10.1093/ecco-jcc/jjx025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
598 Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400.e3. [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052] [Cited by in Crossref: 512] [Cited by in F6Publishing: 445] [Article Influence: 73.1] [Reference Citation Analysis]
599 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis 2018;24:2272-7. [PMID: 29718223 DOI: 10.1093/ibd/izy133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
600 杨旭, 王元钊, 叶妮, 王轶, 张苏闽, 方健, 周惠芬. 中药超声导入对溃疡性结肠炎患者的临床疗效及其细胞因子的影响. 世界华人消化杂志 2013; 21(31): 3450-3455 [DOI: 10.11569/wcjd.v21.i31.3450] [Reference Citation Analysis]
601 Wang Y, Tang Q, Duan P, Yang L. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacol Immunotoxicol 2018;40:476-82. [PMID: 30111198 DOI: 10.1080/08923973.2018.1469145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
602 Martínez González J, Busto Bea V, Mesonero Gismero F, Parejo Carbonell S, Garrido E, López San Román A. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine]. Gastroenterol Hepatol 2013;36:7-10. [PMID: 23195755 DOI: 10.1016/j.gastrohep.2012.08.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
603 Rtibi K, Jabri M, Selmi S, Sebai H, Marie J, Amri M, Marzouki L, El-benna J. Preventive effect of carob (Ceratonia siliqua L.) in dextran sulfate sodium-induced ulcerative colitis in rat. RSC Adv 2016;6:19992-20000. [DOI: 10.1039/c5ra21388f] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
604 Triadafilopoulos G. Glucocorticoid therapy for gastrointestinal diseases. Expert Opinion on Drug Safety 2014;13:563-72. [DOI: 10.1517/14740338.2014.904852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
605 Böhm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol 2014;7:369-83. [PMID: 25285021 DOI: 10.2147/CEG.S35691] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
606 Teixeira FV, Vilela EG, Damião AOMC, Vieira A, Albuquerque IC, Parente JML, Chebli JMF, Ambrogini Junior O, Hossne RS, Miszputen SJ. Ulcerative colitis - treatment with biologicals. Rev Assoc Med Bras (1992) 2019;65:547-53. [PMID: 31066808 DOI: 10.1590/1806-9282.65.4.547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
607 Bautzová T, Rabišková M, Béduneau A, Pellequer Y, Lamprecht A. Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. European Journal of Pharmaceutics and Biopharmaceutics 2012;81:379-85. [DOI: 10.1016/j.ejpb.2012.02.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
608 Pleet JL, Vaughn BP, Morris JA, Moss AC, Cheifetz AS. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment Pharmacol Ther 2014;39:940-8. [PMID: 24605866 DOI: 10.1111/apt.12691] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
609 Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, Lightdale JR, Trenor CC 3rd. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;57:343-7. [PMID: 23752078 DOI: 10.1097/MPG.0b013e31829ce5cd] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 6.6] [Reference Citation Analysis]
610 Burness CB, Keating GM. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. BioDrugs 2013;27:247-62. [PMID: 23580096 DOI: 10.1007/s40259-013-0033-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
611 Ueda N, Isomoto H, Ikebuchi Y, Kurumi H, Kawaguchi K, Yashima K, Ueki M, Matsushima K, Akashi T, Uehara R, Takeshima F, Hayashi T, Nakao K. Endocytoscopic classification can be predictive for relapse in ulcerative colitis. Medicine (Baltimore). 2018;97:e0107. [PMID: 29517688 DOI: 10.1097/md.0000000000010107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
612 Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:255-263. [PMID: 25314574 DOI: 10.3109/00365521.2014.966753] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
613 Islam MS, Grainger SL. Do we know how to use corticosteroids in acute severe ulcerative colitis? Frontline Gastroenterol 2012;3:248-51. [PMID: 28839676 DOI: 10.1136/flgastro-2012-100211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
614 Fornaro R, Caratto E, Caratto M, Sticchi C, Salerno A, Bianchi R, Scabini S, Casaccia M. Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it? Eur Surg 2017;49:108-12. [DOI: 10.1007/s10353-016-0458-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
615 Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
616 Bergeron F, Bouin M, D'Aoust L, Lemoyne M, Presse N. Food avoidance in patients with inflammatory bowel disease: What, when and who? Clin Nutr 2018;37:884-9. [PMID: 28359542 DOI: 10.1016/j.clnu.2017.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
617 Stidham RW, Higgins PDR. Colorectal Cancer in Inflammatory Bowel Disease. Clin Colon Rectal Surg. 2018;31:168-178. [PMID: 29720903 DOI: 10.1055/s-0037-1602237] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 22.3] [Reference Citation Analysis]
618 Papa A, Gerardi V, Marzo M, Felice C, Rapaccini GL, Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. World J Gastroenterol 2014; 20(12): 3173-3179 [PMID: 24695669 DOI: 10.3748/wjg.v20.i12.3173] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
619 Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45. [PMID: 21556038 DOI: 10.1038/ajg.2011.156] [Cited by in Crossref: 160] [Cited by in F6Publishing: 138] [Article Influence: 16.0] [Reference Citation Analysis]
620 Mcconachie S, Wilhelm SM, Kale-pradhan PB. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. Expert Review of Clinical Pharmacology 2017;10:391-400. [DOI: 10.1080/17512433.2017.1283983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
621 van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747-1753. [PMID: 25137415 DOI: 10.1097/mib.0000000000000139] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
622 Permpoon V, Pongpirul K, Anuras S. Ethnic variations in ulcerative colitis: Experience of an international hospital in Thailand. World J Gastrointest Pharmacol Ther 2016; 7(3): 428-433 [PMID: 27602244 DOI: 10.4292/wjgpt.v7.i3.428] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
623 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
624 Bordeianou L, Maguire L. State-of-the-Art Surgical Approaches to the Treatment of Medically Refractory Ulcerative Colitis. J Gastrointest Surg 2013;17:2013-9. [DOI: 10.1007/s11605-013-2312-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
625 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
626 Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. World J Gastroenterol 2016; 22(6): 2030-2045 [PMID: 26877608 DOI: 10.3748/wjg.v22.i6.2030] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
627 Banerjee R, Pal P, Penmetsa A, Kathi P, Girish G, Goren I, Reddy DN. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study. J Clin Gastroenterol 2021;55:702-8. [PMID: 32889959 DOI: 10.1097/MCG.0000000000001416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
628 Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ 2018;21:869-77. [PMID: 29857775 DOI: 10.1080/13696998.2018.1484371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
629 Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014; 20(17): 4980-4986 [PMID: 24803809 DOI: 10.3748/wjg.v20.i17.4980] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
630 Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, Danese S. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021:jjab099. [PMID: 34107013 DOI: 10.1093/ecco-jcc/jjab099] [Reference Citation Analysis]
631 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
632 Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50. [PMID: 22888278 DOI: 10.2147/CPAA.S26556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
633 Saba E, Lee YY, Kim M, Hyun SH, Park CK, Son E, Kim DS, Kim SD, Rhee MH. A novel herbal formulation consisting of red ginseng extract and Epimedium koreanum Nakai-attenuated dextran sulfate sodium-induced colitis in mice. J Ginseng Res 2020;44:833-42. [PMID: 33192127 DOI: 10.1016/j.jgr.2020.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
634 Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010] [Cited by in Crossref: 127] [Cited by in F6Publishing: 106] [Article Influence: 31.8] [Reference Citation Analysis]
635 Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442-450. [PMID: 23461895 DOI: 10.1136/gutjnl-2012-303424] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 11.9] [Reference Citation Analysis]
636 Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, Lieb JG 2nd, Park WG, Rizk MK, Sawhney MS, Shaheen NJ, Wani S, Weinberg DS. Quality indicators for colonoscopy. Gastrointest Endosc. 2015;81:31-53. [PMID: 25480100 DOI: 10.1016/j.gie.2014.07.058] [Cited by in Crossref: 481] [Cited by in F6Publishing: 412] [Article Influence: 68.7] [Reference Citation Analysis]
637 Ahmed O, Nguyen GC. Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. Expert Rev Gastroenterol Hepatol 2016;10:1005-10. [PMID: 27087144 DOI: 10.1080/17474124.2016.1179579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
638 Oliphant K, Cochrane K, Schroeter K, Daigneault MC, Yen S, Verdu EF, Allen-Vercoe E. Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria In Vitro. mSystems 2020;5:e00404-19. [PMID: 31992630 DOI: 10.1128/mSystems.00404-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
639 Con D, De Cruz P. Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR Mhealth Uhealth. 2016;4:e13. [PMID: 26831935 DOI: 10.2196/mhealth.4874] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 8.6] [Reference Citation Analysis]
640 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
641 Sinha SR, Nguyen LP, Inayathullah M, Malkovskiy A, Habte F, Rajadas J, Habtezion A. A Thermo-Sensitive Delivery Platform for Topical Administration of Inflammatory Bowel Disease Therapies. Gastroenterology 2015;149:52-55.e2. [PMID: 25863215 DOI: 10.1053/j.gastro.2015.04.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
642 Mathers B, Williams E, Bedi G, Messaris E, Tinsley A. An Electronic Alert System Is Associated With a Significant Increase in Pharmacologic Venous Thromboembolism Prophylaxis Rates Among Hospitalized Inflammatory Bowel Disease Patients.J Healthc Qual. 2017;39:307-314. [PMID: 27153049 DOI: 10.1097/JHQ.0000000000000021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
643 Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2011;5:411-425. [PMID: 21651358 DOI: 10.1586/egh.11.29] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
644 Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D’Incà R, Terpin M, Lombardi G. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006-1010. [PMID: 21830282 DOI: 10.1002/ibd.21838] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 8.0] [Reference Citation Analysis]
645 Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. Clin Appl Thromb Hemost 2017;23:501-10. [DOI: 10.1177/1076029616632906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
646 Pohjonen J, Nurmi R, Metso M, Oksanen P, Huhtala H, Pörsti I, Mustonen J, Kaukinen K, Mäkelä S. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J 2019;12:645-51. [PMID: 31583091 DOI: 10.1093/ckj/sfz004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
647 Velayos FS, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Abramson O, Perry GS, Herrinton LJ. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology. 2010;139:1511-1518. [PMID: 20659470 DOI: 10.1053/j.gastro.2010.07.039] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
648 Sandborn WJ, Colombel JF, D’Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204-213. [PMID: 23173821 DOI: 10.1111/apt.12145] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 9.9] [Reference Citation Analysis]
649 Bilal M, Singh S, Lee H, Khosa K, Khehra R, Clarke K. Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Ann Gastroenterol 2017;30:192-6. [PMID: 28243040 DOI: 10.20524/aog.2016.0114] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
650 Lichtenstein GR, Zakko S, Gordon GL, Murthy U, Sedghi S, Pruitt R, Merchant K, Bortey E, Forbes WP. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials. Aliment Pharmacol Ther. 2012;36:126-134. [PMID: 22617015 DOI: 10.1111/j.1365-2036.2012.05142.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
651 Afzali A, Ogden K, Friedman ML, Chao J, Wang A. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. Journal of Medical Economics 2017;20:409-22. [DOI: 10.1080/13696998.2017.1285779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
652 Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis 2015;9:738-46. [PMID: 26094251 DOI: 10.1093/ecco-jcc/jjv101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
653 Aletaha N, Dadvar Z, Salehi B, Ketabi Moghadam P, Niksirat A, Jowkar A, Taslimi R, Allameh SF, Ebrahimi Daryani N. Clinical and Pathological Features of Ulcerative Colitis in Patients with and without Clostridium Difficile Infection; An Observational Study. Middle East J Dig Dis 2019;11:17-23. [PMID: 31049178 DOI: 10.15171/mejdd.2018.123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
654 Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-wood M. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012;36:755-64. [DOI: 10.1111/apt.12013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
655 Pinto N, Cohn SL, Dolan ME. Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res 2012;18:2791-800. [PMID: 22589487 DOI: 10.1158/1078-0432.CCR-11-1938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
656 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
657 Aprodu A, Mantaj J, Raimi-Abraham B, Vllasaliu D. Evaluation of a Methylcellulose and Hyaluronic Acid Hydrogel as a Vehicle for Rectal Delivery of Biologics. Pharmaceutics 2019;11:E127. [PMID: 30893796 DOI: 10.3390/pharmaceutics11030127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
658 Zhou H, Qian H. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. Drug Des Devel Ther 2018;12:2601-9. [PMID: 30174414 DOI: 10.2147/DDDT.S170676] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
659 Patel H, Latremouille-viau D, Burne R, Shi S, Adsul S. Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz022. [DOI: 10.1093/crocol/otz022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
660 Sandborn WJ, Peyrin-biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:550-61. [DOI: 10.1053/j.gastro.2019.10.035] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 37.0] [Reference Citation Analysis]
661 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
662 Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Translational Research 2015;165:270-82. [DOI: 10.1016/j.trsl.2014.09.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 12.3] [Reference Citation Analysis]
663 D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2017;46:292-302. [PMID: 28568974 DOI: 10.1111/apt.14164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
664 Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol. 2011;4:163-172. [PMID: 21904462 DOI: 10.2147/ceg.s14558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
665 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 125] [Article Influence: 38.0] [Reference Citation Analysis]
666 Sengupta N, Yee E, Feuerstein JD. Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci 2016;61:980-9. [DOI: 10.1007/s10620-015-3979-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
667 Russo L, Schneider G, Gardiner MH, Lanes S, Streck P, Rosen S. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine. Eur J Clin Pharmacol 2014;70:709-17. [PMID: 24609467 DOI: 10.1007/s00228-014-1660-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
668 Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-1563. [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 106] [Article Influence: 18.1] [Reference Citation Analysis]
669 Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis 2017;23:494-501. [PMID: 28296817 DOI: 10.1097/MIB.0000000000001048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
670 Sano Y, Chiu HM, Li XB, Khomvilai S, Pisespongsa P, Co JT, Kawamura T, Kobayashi N, Tanaka S, Hewett DG, Takeuchi Y, Imai K, Utsumi T, Teramoto A, Hirata D, Iwatate M, Singh R, Ng SC, Ho SH, Chiu P, Tajiri H. Standards of diagnostic colonoscopy for early-stage neoplasia: Recommendations by an Asian private group. Dig Endosc 2019;31:227-44. [PMID: 30589103 DOI: 10.1111/den.13330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
671 Sussman DA, Barkin JA, Martin AM, Varma T, Clarke J, Quintero MA, Barkin HB, Deshpande AR, Barkin JS, Abreu MT. Development of Advanced Imaging Criteria for the Endoscopic Identification of Inflammatory Polyps. Clin Transl Gastroenterol 2015;6:e128. [PMID: 26583503 DOI: 10.1038/ctg.2015.51] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
672 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:389-400. [PMID: 28653751 DOI: 10.1111/apt.14203] [Cited by in Crossref: 170] [Cited by in F6Publishing: 149] [Article Influence: 42.5] [Reference Citation Analysis]
673 Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:229-40. [PMID: 33513294 DOI: 10.1002/cpdd.899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
674 Martinez B, Dailey F, Almario CV, Keller MS, Desai M, Dupuy T, Mosadeghi S, Whitman C, Lasch K, Ursos L, Spiegel BM. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. Inflammatory Bowel Diseases 2017;23:1057-64. [DOI: 10.1097/mib.0000000000001110] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
675 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 54.0] [Reference Citation Analysis]
676 Pence IJ, Beaulieu DB, Horst SN, Bi X, Herline AJ, Schwartz DA, Mahadevan-Jansen A. Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopy. Biomed Opt Express 2017;8:524-35. [PMID: 28270965 DOI: 10.1364/BOE.8.000524] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 6.8] [Reference Citation Analysis]
677 Shah SC, Naymagon S, Cohen BL, Sands BE, Dubinsky MC. There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. J Clin Gastroenterol 2018;52:333-8. [PMID: 28009685 DOI: